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The Treatment of Breast Cancer Tumor Growth and Metastasis With an AntiMMP9 DNAzyme
Abstract
BACKGROUND: Tumor cell proliferation, invasion and metastasis are known to be mediated, at least in
part, through degradation of basement membrane by neutral metalloproteinases (MMP) produced by
tumor and stromal cells. MMP-9 is known to play a significant role in breast tumor cell invasion and
metastasis via degradation of ECM components and activation of cytokines and chemokines. MMP-9 is
known to cleave type IV collagen, one of the most abundant collagens of the extracellular matrix. Our lab
has found that the fully processed (68 kDa) form of MMP-9 generated in tumor and stromal cells is also
capable of cleaving type I collagen molecule with similar characteristics of MMP‑1. This observation
raises questions regarding the significance of each MMP in tumor cell invasion and metastases. Thus, in
combating tumor growth and invasion, understanding the mechanism of substrate specificity and design
of a novel therapeutic compound that is capable of specifically down regulating MMP-9 expression are of
interest.
METHOD: DNAzymes are catalytic oligonucleotides that bind to and cleave specific mRNA, resulting in a
decreased protein expression. The safety and efficacy of anti-MMP-9 DNAzyme (AM9D) in vivo was
determined by injecting 35S‑labeled AM9D (35S-AM9D) into the tail vein of healthy and MMTV-PyMT
transgenic mice and the amount of 35S-AM9D accumulated in different tissues was measured as a
function of time. The effect of AM9D treatment on breast tumor progression was tested by four
once‑weekly intratumoral injections of two concentrations of AM9D into mammary tumors of MMTVPyMT transgenic mice at early stages of tumor development. The tumor sizes were measured at the end
of the experiments. The effect of AM9D treatment on early stage experimental metastasis and survival
was evaluated by injecting FVB female mice with 1x106 luciferase labeled mammary tumor epithelial cells
(luc‑MTEC) isolated from MMTV‑PyMT mice and treating the animals with AM9D, control DNAzyme, or
PBS for 3 weeks or up to 10 weeks, respectively.
The mechanism of substrate specificity of 68 kDa MMP‑9 was determined by generating a series of
truncated and site directed mutant forms of MMP‑9. Specific amino acid residue in sequence
444

PRPEPEPRPPTTT456 in the hinge region responsible for substrate selectivity of the enzyme was then

identified by alanine‑scanning site directed mutagenesis. The charged amino acid residues (Arg445,
Glu447, Glu449, and Arg451) were individually replaced by Ala and the proteolytic activity of the mutant
enzymes toward Mca‑PLGL(Dpa)AR‑NH2 , gelatin, and type I collagen was determined.
RESULTS: Treatment of MDA‑MB‑231 breast cancer cell line with AM9D in vitro resulted in decreased
invasion potential of the cells and intratumoral treatment of MMTV‑PyMT mice in vivo resulted in delayed
rate of tumor growth and retarded final tumor volume by up to 51%. This decrease in tumor growth was
correlated with decreased MMP-9 protein production within the treated tumor tissues. Tumors treated
with AM9D were also less vascular compared to control and untreated tumors. Furthermore, DNAzyme
administered IV is distributed to major organs including lung, without showing any organ toxicity.
Intravenous administration of AM9D and control DNAzyme in animals bearing luc‑MTECs were able to
decrease the number of gross lung macro metastasis. In addition, AM9D treatment increased
progression‑free survival but did not have an effect on overall survival of animals inoculated with
luc‑MTECs compared to control DNAzyme and PBS treatment. These data indicate that AM9D can be
used individually or as an adjuvant to current chemotherapy for breast cancer.
To further illuminate the role of MMP-9 in tumor growth and metastases the mechanism of substrate

specificity of the enzyme was studied. Site directed and deletion mutagenesis revealed that interaction of
Glu415 in the active site with Glu447 and/or Arg451 in the hinge region makes the active site rigid,
preventing full length MMP-9 from cleaving type I collagen. Disruption of this interaction, on the other
hand, provides the flexibility necessary for the enzyme's active site to change conformation and be able to
bind and cleave type I collagen substrate.
CONCLUSION: Given that MMP-9 is capable of cleaving type I collagen and its down regulation hinders
the development of breast cancer in an animal model, AM9D could prove useful as an adjuvant therapy
against breast carcinoma cell invasion.
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ABSTRACT
BACKGROUND: Tumor cell proliferation, invasion and metastasis are known to
be mediated, at least in part, through degradation of basement membrane by neutral
metalloproteinases (MMP) produced by tumor and stromal cells. MMP-9 is known to
play a significant role in breast tumor cell invasion and metastasis via degradation of
ECM components and activation of cytokines and chemokines. MMP-9 is known to
cleave type IV collagen, one of the most abundant collagens of the extracellular matrix.
Our lab has found that the fully processed (68 kDa) form of MMP-9 generated in tumor
and stromal cells is also capable of cleaving type I collagen molecule with similar
characteristics of MMP-1. This observation raises questions regarding the significance of
each MMP in tumor cell invasion and metastases. Thus, in combating tumor growth and
invasion, understanding the mechanism of substrate specificity and design of a novel
therapeutic compound that is capable of specifically down regulating MMP-9 expression
are of interest.
METHOD: DNAzymes are catalytic oligonucleotides that bind to and cleave
specific mRNA, resulting in a decreased protein expression. The safety and efficacy of
anti-MMP-9 DNAzyme (AM9D) in vivo was determined by injecting 35S-labeled AM9D
(35S-AM9D) into the tail vein of healthy and MMTV-PyMT transgenic mice and the
amount of 35S-AM9D accumulated in different tissues was measured as a function of
time. The effect of AM9D treatment on breast tumor progression was tested by four
once-weekly intratumoral injections of two concentrations of AM9D into mammary
tumors of MMTV-PyMT transgenic mice at early stages of tumor development. The
tumor sizes were measured at the end of the experiments. The effect of AM9D treatment
on early stage experimental metastasis and survival was evaluated by injecting FVB
female mice with 1x106 luciferase labeled mammary tumor epithelial cells (luc-MTEC)
isolated from MMTV-PyMT mice and treating the animals with AM9D, control
DNAzyme, or PBS for 3 weeks or up to 10 weeks, respectively.
The mechanism of substrate specificity of 68 kDa MMP-9 was determined by
generating a series of truncated and site directed mutant forms of MMP-9. Specific
amino acid residue in sequence 444PRPEPEPRPPTTT456 in the hinge region responsible
for substrate selectivity of the enzyme was then identified by alanine-scanning site
directed mutagenesis. The charged amino acid residues (Arg445, Glu447, Glu449, and
Arg451) were individually replaced by Ala and the proteolytic activity of the mutant
enzymes toward Mca-PLGL(Dpa)AR-NH2, gelatin, and type I collagen was determined.
RESULTS: Treatment of MDA-MB-231 breast cancer cell line with AM9D in
vitro resulted in decreased invasion potential of the cells and intratumoral treatment of
MMTV-PyMT mice in vivo resulted in delayed rate of tumor growth and retarded final
tumor volume by up to 51%. This decrease in tumor growth was correlated with
decreased MMP-9 protein production within the treated tumor tissues. Tumors treated
with AM9D were also less vascular compared to control and untreated tumors.
Furthermore, DNAzyme administered IV is distributed to major organs including lung,
v

without showing any organ toxicity. Intravenous administration of AM9D and control
DNAzyme in animals bearing luc-MTECs were able to decrease the number of gross
lung macro metastasis. In addition, AM9D treatment increased progression-free survival
but did not have an effect on overall survival of animals inoculated with luc-MTECs
compared to control DNAzyme and PBS treatment. These data indicate that AM9D can
be used individually or as an adjuvant to current chemotherapy for breast cancer.
To further illuminate the role of MMP-9 in tumor growth and metastases the
mechanism of substrate specificity of the enzyme was studied. Site directed and deletion
mutagenesis revealed that interaction of Glu415 in the active site with Glu447 and/or Arg451
in the hinge region makes the active site rigid, preventing full length MMP-9 from
cleaving type I collagen. Disruption of this interaction, on the other hand, provides the
flexibility necessary for the enzyme’s active site to change conformation and be able to
bind and cleave type I collagen substrate.
CONCLUSION: Given that MMP-9 is capable of cleaving type I collagen and its
down regulation hinders the development of breast cancer in an animal model, AM9D
could prove useful as an adjuvant therapy against breast carcinoma cell invasion.
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CHAPTER 1.

INTRODUCTION

BACKGROUND
Breast Cancer
Breast cancer is one of the leading causes of cancer deaths in women, second only
to lung cancer [1]. Breast cancer is divided into three subtypes based on the tumor cells
expression of estrogen receptor (ER), progesterone receptor (PR), and/or HER2. The
aforementioned subtypes of breast cancer are known as luminal A (ER or PR+/HER2-),
luminal B (ER or PR+/HER2+), and triple negative (ER-/PR-/HER2-) [2]. The American
Cancer Society estimated that in 2010 there would be 207,090 new cases of invasive and
57,010 new cases of non-invasive breast cancer diagnosed in women. In 2010, about
39,840 women were expected to die as a result of breast cancer. The spread of cancer
cells to distant organs, metastasis, is responsible for the majority of morbidity and
mortality [3-5]. In the case of breast cancer, metastasis affects the lungs, regional lymph
nodes and bone, while less frequently affecting brain and liver [6]. This metastasis and
eventual tumor growth at distant sites depends on interaction between tumor cells,
stromal cells, and the host microenvironment [7]. Since the main event separating those
that survive breast cancer and those who fall victim to breast cancer is metastasis, it is as
important to develop therapeutic strategies against the metastatic process as for any other
process in the breast cancer spectrum.
It has been widely hypothesized that metastasis occurs when cells from the
primary tumor undergo sequential steps to make them more adaptable to seed tumors in
distant organs. These sequential steps include the transition of epithelial cells to
mesenchymal like cells (epithelial to mesenchymal transition; EMT), degradation of the
extracellular membrane (ECM), intravasation, extravasation, and finally transition back
to epithelial like cells (mesenchymal to epithelial transition; MET) [8]. This transition has
been shown to involve matrix metalloproteinases (MMP) produced by tumor and stromal
cells [9]. These enzymes enable the invasion of carcinoma cells into adjacent normal
tissue by degrading the extracellular (ECM) and basement membrane components.
Matrix Metalloproteinases (MMP)
MMPs are a family of over 24 proteolytic enzymes and essential regulators of
cells microenvironment [10]. These enzymes are secreted as catalytically latent species,
which are processed to their activated forms in vivo by other proteinases [11]. Most
human MMPs are categorized into five main subclasses based on their substrate
specificity, collagenases (MMP1, MMP8, and MMP13), stromelysin (MMP3, MMP10,
MMP11, MMP7 and MMP26), gelatinases (MMP2 and MMP9), membrane type MMPs
(MMP14, MMP15, MMP16, MMP17, MMP24, and MMP25) [10, 11] and
metalloelastase (MMP-12) [12]. MMPs cleave virtually all components of the ECM and
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overlap in their substrate specificity. Collagenases can cleave native fibrillar collagen
types I, II, and III [13]. Although less well studied, the collagenases can also cleave
collagen types VII and X as well as gelatin, aggrecan, entactin, and tenascin [14].
Stromylysins digest native collagen types III, IV, V, IX, X, and XI, as well as, tenascin,
gelatin, aggrecan, and many other substrates [14]. Gelatinases digest elastin, aggrecan,
and collagen types IV, V, and XI [14]. They also act synergistically with interstitial
collagenase in the degradation of fibrillar collagens. Recent studies have shown that
MMP-2 can cleave native type I collagen in the same position as MMP-1 [15], and
MMP-9 cleaves 2 chains of type I collagen [16]. Finally, a few of the MT-MMP
substrates are collagens type I, II, and III, gelatin, casein, fibronectin, laminin,
vitronectin, and entactin [14].
As evidenced by their substrate specificity, MMPs play a significant role in
normal and pathological conditions that involve matrix degradation and remodeling [17].
This includes, but is not limited to, wound healing, post partum involution, congestive
heart failure, rheumatoid arthritis, osteoarthritis, and cancer (reviewed in [18-22]). In
cancer, degradation of the ECM by MMPs not only enhances tumor invasion, but also
affects tumor cell behavior and leads to cancer progression [10].
Metastasis, a multi step process, involves dissemination of cells from the primary
tumor to distant organs or tissues and the formation of secondary tumors. Expression of
MMPs apparently leads to dissociation of cell-cell and cell-ECM adhesion through the
processing of cadherins, thereby leading to EMT initiation [8, 23, 24]. This transition can
lead to increased extracellular proteolytic activity further promoting migration. MMPs
are also capable of affecting cell regulatory signaling, directly or indirectly, within the
extracellular microenvironment, which ultimately affects the cells intracellular signaling
[25]. This is achieved by their role in the bioavailability of multiple growth factors and
cytokines [10, 25]. MMPs also cleave insulin-like growth factors and release
transmembrane precursors of growth factors, including TGF-, which aids in
proliferation [10]. Thus, MMPs are important through their ability to affect tumor
initiation and growth via cell adhesion independency, evasion of apoptosis, disruption of
proper cell division, and as mediators of metastasis during late stage malignancy [25].
MMP-9 in Cancer
It has been suggested that the production of MMPs in general and MMP-9 in
particular is one of the most important factors for migration of tumor cells into the
bloodstream or lymphatic vessels, or into adjacent normal tissues [26, 27]. MMP-9
(gelatinase B) has been shown to be closely associated with invasion and metastasis [28,
29]. MMP-9 degrades type IV collagen, one of the most abundant collagens in the ECM
[22], and is involved in angiogenesis and proliferation. With the use of multistage
pancreatic carcinogenesis in a transgenic RIP1-Tag2 mouse model, MMP-9 was shown to
be up-regulated in angiogenic islets, leading to an increase in the bioavailability of VEGF
[30]. Xu, et al. evidenced that MMP-9’s cleavage of type IV collagen exposes an
otherwise hidden HUIV26 cryptic site which is important in angiogenesis and tumor
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growth in vivo [31]. Rao, et al. have demonstrated the down regulation of MMP-9
increased 1-integrin which leads to ERK activation and apoptosis through one of two
mechanisms: (1) release of cytochrome C into the cytosol and/or (2) increase in NF-kB
activation, which both lead to subsequent activation of caspase 3 [32]. Although few cell
types express MMP-9 constitutively, the majority of human metastatic tumor cells (i.e.
melanoma, fibrosarcoma, breast adenocarcinoma, glioma, etc.) that have been tested
consistently show elevated MMP-9 activity compared with benign control cells [33-36].
In addition, tumor cells stably expressing the MMP-9 cDNA have been shown to
metastasize in nude mice [37]. Furthermore, inhibition of MMP-9 activity has been
demonstrated to block the invasive behavior of breast carcinoma cells, MDA-MB-231
[38]. Thus, inhibition of MMP-9 expression can be used as a therapeutic modality to
decrease growth and invasion of tumor cells.
Analyses of the primary structures of MMPs revealed that these proteins could be
divided into several distinct domains with apparent specific functions (Figure 1-1). A
typical secreted MMP has three major domains: NH2-terminal prodomain, central
catalytic domain, and COOH-terminal hemopexin-like domain [18, 27]. The
characterization of MMP-9 revealed two additional domains, one with homology to the
gelatin-binding region of fibronectin and the other with a collagen-like sequence [39].
The fibronectin-like gelatin binding domain has been shown to be important for the
gelatinolytic and type V collagenolytic activity of the enzyme [40]. Structural
similarities among MMP members have made it very difficult to develop specific
synthetic inhibitor for MMP-9 as a potential cancer therapeutic agent. The lack of
specificity of most active site directed MMP inhibitors that entered clinical trials made

Figure 1-1.

Structural domains of matrix metalloproteinases.

This is a schematic diagram showing the main structural domains of Collagenases
(MMP-1) and Gelatinases (Gelatinase B, MMP-9; Gelatinase A, MMP-2). Gelatinases
contain two additional domains compared to collagenases, the gelatin-binding domain
and the collagen-like domain.
3

them more harmful than helpful [41]. For example, Batimastat, the first synthetic MMP
inhibitor studied in humans, showed reduced growth of primary tumor, onset of distant
metastases, and even prolonged survival of animals with pancreatic, orthotopic colon, or
orthotopic liver tumor [42-44]. In addition, Marimastat, a derivative of Batimastat
significantly increased progression-free survival in the patients with inoperable gastric
cancer, without improving overall survival [45]. Despite favorable results of these
synthetic MMP inhibitors in animal systems and human clinical trials, they lead to
significant side effects, which include but are not limited to fatigue, anorexia, nausea,
vomiting, asthenia, and inflammatory polyarthritis [46, 47]. These multiple side effects
associated with usage of the non-specific MMP inhibitors in clinical trials are
comprehensible since as stated above, MMPs are required for normal physiological
processes such as cell growth and remodeling, ovulation, and wound healing. In addition,
two MMP members, MMP-3 and -8, have been identified as cancer anti-targets because
their down regulation results in initiation of the disease or deleterious alteration in disease
progression [27]. In order to over come this problem, the mechanism of substrate
specificity of MMP-9 must be identified and considered in the design of the specific
inhibitor to be used for cancer therapy.
The role of the hemopexin-like carboxyl terminal domain of MMP-9 is of interest,
since we have recently shown that it dictates substrate specificity of the enzyme (please
see below). The role and significance of collagen-like and hemopexin-like carboxyl
terminal domains in substrate specificity of MMP-9 has been investigated in Chapter 5.
DNAzymes as Novel Treatments for Cancer
Over the past few years, DNAzymes have been used in vitro to selectively inhibit
or modify specific mRNA levels in mammalian cell cultures [48]. DNAzymes are
catalytic DNA molecules that in the absence of proteins bind to and cleave specific
mRNA sequences, which results in the decreased expression of the encoded protein [49]
(Figure 1-2).
DNAzymes have emerged as novel, highly selective inhibitors or modulators of
gene expression [50]. Khachigian and colleagues have reported that the DNAzymes
targeting early growth response factor-1 (Egr-1) mRNA inhibits neointimal formation
after balloon injury to the rat carotid artery wall and reduce intimal thickening after
stenting pig coronary arteries. DNAzyme targeting c-Jun caused repair of injured rat
carotid arteries [51]. Upregulation of Aurora kinase A has been shown to be important in
carcinogenesis of prostate cancer. DZ2, an Aurora kinase A specific DNAzyme was
shown to strongly inhibit Aurora kinase A in a prostate cancer cell line in vitro and
inhibit tumor growth of human prostate cancer xenografts in nude mice [52]. Finally, a
DNAzyme targeting vascular endothelial growth factor receptor 2 (VEGFR2)
significantly inhibited the growth of breast tumors derived from xenografting
MDA-MB-435 cells into nude mice by inducing apoptosis [53]. These data demonstrate
that these small nucleotide mRNA cleaving sequences can potentially be designed and
administered to target specific genes with relative lack of toxicity. DNAzymes have
4

Figure 1-2.

Composition of the 10-23 catalytic motifs.

The DNA enzyme (bottom strand) binds the RNA substrate (top strand) through
Watson-Crick pairing. Cleavage occurs at the position indicated by the arrow. R=Purine
(A or G); Y=Pyrimidine (U or C). Reprinted with permission from Santoro SW, Joyce
GF (1997). A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A
94: 4262-4266.
excellent potential as a biotherapy against matrix metalloproteinases.
As stated above, since DNAzyme molecules can be designed to target a specific
gene with relative lack of toxicity, it is expected that specific down regulation of MMP-9
by DNAzyme will prevent tumor cell invasion and metastasis while generating a
minimum side effect.
Design and In Vitro Efficacy of Anti-MMP-9 DNAzyme (AM9D)
To test whether down regulation of MMP-9 by an MMP-9 mRNA targeted
DNAzyme could be used as a treatment strategy for cancer, Dr. Hasegawa, a postdoctoral
fellow in our laboratory, designed several anti-MMP-9 DNAzymes (AM9D) according to
putative DNAzyme target sites in the predicted secondary structure of MMP-9 mRNA
and selected the most efficient AM9D with respect to its activity toward RNA substrate.
As shown in Figure 1-3a, only AM9D-2 (lane 3) and AM9D-5 (lane 6) were able to
efficiently cleave over 85% of the RNA substrate in 2 h at 37 ˚C as determined by the
density of the RNA fragment products. These reactions were time dependent as a longer
incubation of the RNA substrate with the AM9D-2 and AM9D-5 led to complete
cleavage of the RNA molecule (data not shown). The AM9D-1, scrambled control, and
sense control DNAzymes (lanes 2, 7 and 8, respectively) at the same concentration did
not have any activity toward the RNA substrate. AM9D-3 and -4 (lanes 4 and 5) were
able to cleave only ~ 25% of the RNA substrate. AM9D-5 (referred to in this body of
work as AM9D) and scrambled control DNAzyme was used for further studies.
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Figure 1-3.

Efficacy of anti-MMP-9 DNAzyme (AM9D) in vitro.

(a) Urea-Polyacrylamide gel electrophoresis of cleaved MMP-9-RNA by DNAzyme.
Anti MMP-9 DNAzymes, scrambled, or sense control DNAzymes (12.5 μM) were
incubated with MMP-9 RNA substrate (764 nt, 0.48 μM) for 2 h at 37 ˚C and the
products were analyzed by polyacrylamide-urea gel. Lane 1, RNA substrate alone;
lane 2, AM9D-1; lane 3, AM9D-2; lane 4, AM9D-3; lane 5, AM9D-4; lane 6, AM9D-5;
lane 7, Scrambled control; and lane 8, Sense control DNAzymes. The RNA bands were
visualized by Ethidium Bromide staining. The lowest molecular weight bands are
DNAzyme. (b) AM9D reduced MMP-9 mRNA level. MMP-9 stably transfected COS-7
cells (COS-7 NG) were transfected with Oregon Green 488 labeled DNAzymes.
Positively transfected cells were identified by flow cytometry. Total RNA was isolated
and MMP-9, MMP-2, and ß-actin mRNA were amplified by RTPCR. The PCR products
were subjected to agarose gel and visualized by Ethidium Bromide staining. Lane 1,
AM9D-5; lane 2, control DNAzyme; lane 3, Cells treated with DOTAP transfection
reagent only and lane 4, the PCR product from parental COS-7 cells (non-transfected
with MMP-9). (c) AM9D decreased MMP-9 production. Culture media from MMP-9
stably transfected COS-7 cells (COS-7 NG) treated with DOTAP alone (lane 1), control
DNAzyme (lane 2), and AM9D-5 (lane 3) were separated on gelatin zymogram gel. As
shown, AM9D-5 down regulates production of MMP-9 in COS-7 NG cells. (d) AM9D
decreased the invasive behavior of human MDA-MB-231 breast cancer cells. The
percentage ratio of carcinoma cells invading the Matrigel Matrix after treatment with
AM9D-5 against that of cells treated with control DNAzyme after 24 h. The AM9D-5
transfected cells showed a 43% reduction in cell invasion compared to control DNAzyme
transfected cells.
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To assess the effect of AM9D-5 on MMP-9 production in vitro, monkey kidney
cells lacking MMP-9 (COS-7 cells, Figure 1-3b, lane 4) were stably transfected with
MMP-9 cDNA to constitutively express the protein. The effect of AM9D-5 on the
production of MMP-9 in the stably transfected cells (COS-7 NG) was then examined by
transiently transfecting the cells with different amounts of either control DNAzyme or
AM9D-5 using Gene PORTER (Genlantis, San Diego, CA). Twenty-four h after
transfection, the cells were harvested, total RNA was extracted, and condition media
were examined for the presence of MMP-9 mRNA and protein by RT-PCR (Figure 1-3b)
and by gelatin gel zymography (Figure 1-3c), respectively. As demonstrated in Figure
1-3b and c, AM9D-5 was able to significantly reduce the level of the MMP-9 mRNA
(Figure 1-3b, lane 1) and protein as evidenced by the low enzyme activity in AM9D-5
treated COS-7 NG cells (Figure 1-3c, lane 3) compared to non-treated and control
DNAzyme treated cells (Figure 1-3c, lanes 1 and 2, respectively).
To demonstrate the specificity of AM9D toward MMP-9 mRNA its activity
toward MMP-2 mRNA, a closely related enzyme to MMP-9, was determined. COS-7
cells constitutively express MMP-2 (Figure 1-3b and c). Stably transfecting COS-7 cells
with MMP-9 cDNA (COS-7 NG) and treating the cells with AM9D-5 did not have any
effect on MMP-2 mRNA (Figure 1-3b) or protein (Figure 1-3c) expression levels. This
data clearly demonstrates that the AM9D-5 is very specific and it only affects the MMP-9
production in cells.
To determine the effect of decreased MMP-9 mRNA expression on the invasive
behavior of cancer cells, MDA-MB-231 highly invasive breast cancer cells were
transiently transfected with fluorescently labeled AM9D-5 or control DNAzyme, FACS
sorted and the invasive behavior of the sorted cells was determined using ECMatrix™
(Millipore, Billerica, MA) invasion chamber. The mean invasion potential of
MDA-MB-231 cells decreased by 43% when transfected with AM9D-5 compared to
control DNAzyme treated cells (Figure 1-3d). These data indicate that MMP-9
significantly contributes to the invasive behavior of MDA-MB-231 tumor cells and
provides evidence that AM9D treatment significantly and specifically reduces MMP-9
production and suppresses the invasive behavior of breast tumor cells in vitro. Thus,
AM9D may be a useful anti-tumorigenic and anti-metastatic agent in vivo.
RESEARCH OBJECTIVES AND SPECIFIC AIMS
Objective
The objective of this proposal was to evaluate the efficacy of an MMP-9 targeted
DNAzyme as a therapy in treating breast carcinoma and preventing lung metastasis. If
anti-MMP-9 DNAzyme (AM9D) therapy is proven useful in reducing tumor growth and
preventing metastasis in an animal model of breast cancer, this will be an important step
in the preclinical development of a new biotherapy with excellent potential for expanding
the standard of care for breast cancer patients.
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Specific Aim 1
The first aim of this body of work was to test the efficacy of anti-MMP-9
DNAzyme oligonucleotides on tumor growth in MMTV-PyMT transgenic mice. This
was accomplished by intratumorally injecting control DNAzyme or AM9D into
mammary tumors once a week, for 4 weeks, at an early palpable tumor size. Tumor sizes
were measured weekly and the animals were sacrificed at a selected time point (one week
after the 4th injection). The efficacy of MMP-9 downregulation by AM9D on the rate of
tumor growth, final tumor load, development of new vasculature, and tumor cell survival
was evaluated.
Specific Aim 2
The second aim of this body of work was to determine the distribution, clearance,
and cytotoxicity of AM9D. This was accomplished by intravenously injecting
35
S-labeled DNAzyme ([35S]-DNAzyme) molecule into normal and tumor-bearing
MMTV-PyMT mice, sacrificing mice at various time points (2 h -7 days), and
determining the amount of DNAzyme in organs and mammary tumors. To determine
organ toxicity by DNAzyme in general and the anti-MMP-9 DNAzyme (AM9D) in
particular, mice were injected with PBS or escalating concentrations (200 g, 650 g, or
1500 g) of AM9D or control DNAzyme. Mice were sacrificed on day 7 post treatment
and a Pathologist evaluated major organs for any signs of toxicity.
Specific Aim 3
The third aim of this body of work was to determine the effect of AM9D on
experimental metastasis. To accomplish this goal normal FVB mice were injected with
luciferase labeled mammary tumor epithelial cells (luc-MTEC) derived from the
MMTV-PyMT transgenic mice used in the experiments described in specific aim 1. Mice
received weekly intravenous injections of AM9D, control DNAzyme, or PBS. These
mice were sacrificed on day 21 or when they displayed signs of lethargy due to lung
tumor burden to assess the role of AM9D on early stage experimental metastasis and
overall survival, respectively.
Specific Aim 4
The fourth aim of this body of work was to determine the mechanism of substrate
specificity of MMP-9. As stated above, degradation of basement member components by
MMP is one of the first steps in tumor cell invasion and metastasis. Our data indicate that
contrary to a general belief that MMP-9 only cleaves types IV and V and XI collagen,
MMP-9 generated by tumor and stroma cells is also capable of cleaving type I collagen.
Thus, understanding the mechanism behind collagen substrate specificity of MMP-9
sheds light on its role in metastasis, the major cancer-surviving determinant. Specific
8

domain(s) and amino acid residues responsible for substrate specificity of the enzyme
were identified by deletion and Ala scanning site directed mutagenesis of the MMP-9
molecule.
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CHAPTER 2.

TREATMENT OF TUMOR GROWTH WITH AM9D
INTRODUCTION

Accumulating evidence suggests that production of matrix metalloproteinase-9
(MMP-9) by tumor and stroma cells is one of the most important factors for metastatic
behavior of tumor cells [8, 23, 54]. MMP-9 is a member of the matrix metalloproteinase
family of enzymes, which play an important role in normal physiological responses,
including wound healing and bone formation [55]. Some MMPs, including MMP-9,
become deregulated during tumorigenesis and are associated with pro-oncogenic events
such as neo-angiogenesis, tumor cell proliferation and metastasis [9]. For example,
MMP-9 was shown to be upregulated in angiogenic islets of the RIP-Tag2 transgenic
mouse model of pancreatic cancer, leading to an increase in the distribution of VEGF, a
potent pro-angiogenic factor [30]. Moreover, high levels of MMP-9 expression in breast
cancers have been shown to be positively correlated with enhanced tumor cell invasion
and metastasis [28, 29] and with enhanced progression and poor prognosis [9].
MMP-9 is conserved across several species (human, chimpanzee, dog, cow,
mouse, rat, chicken, zebrafish, and A.thaliana). MMP-9 degrades type IV collagen, one
of the most abundant collagens in the extracellular matrix (ECM) [56], which may
stimulate local invasion, the first step in metastasis. In addition, MMP-9 also cleaves
pro-cytokines, chemokines, and growth factors, thereby modifying their biological
activity [10, 25, 57]. In addition, tumor cells that stably express MMP-9 cDNA have been
shown to have enhanced metastastic ability [37]. Thus, inhibition of MMP-9 expression
by our Anti-MMP-9 DNAzymes could be a useful therapeutic modality to decrease the
growth and invasive properties of tumor cells.
As described previously, DNAzymes have been used by several investigators to
selectively inhibit or modulate different gene expressions in vivo [50]. Khachigian and
colleagues have reported that the DNAzymes targeting early growth response factor-1
(Egr-1) mRNA inhibits neointimal formation after balloon injury to the rat carotid artery
wall and reduce intimal thickening after stenting pig coronary arteries. DNAzyme
targeting c-Jun caused repair of injured rat carotid arteries [51]. Finally, a DNAzyme
targeting vascular endothelial growth factor receptor 2 (VEGFR2) significantly inhibited
the growth of breast tumors derived from xenografting MDA-MB-435 cells into nude
mice [53].
The purpose of the present study was to evaluate the effect of AM9D on breast
tumor growth in the MMTV-PyMT mouse model of breast cancer. It is demonstrated for
the first time that once weekly intratumoral injection of AM9D, in the absence of any
carrier molecule, for four weeks was sufficient to significantly reduce the rate of tumor
growth and final tumor load in a dose dependent and statistically significant manner
(p0.05). Together, the data presented here justify the further development of AM9D for
its potential as an anti-tumor agent and as an ideal candidate for breast cancer therapy.
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MATERIALS AND METHODS
DNAzyme
All DNA oligonucleotides used in these experiments were synthesised by
Integrated DNA Technology (Coralville, IA). The sequence of the DNAzyme targeting
mRNA of human and mouse MMP-9 is, 5'-GTGGTGCCAGGCTAGCTACAACGA
TTGAGGCG-3’. In the control DNAzyme, 5'-CTAGTCAGCGGCTAGCTACAACG
ATAAGCTGCT-3', the catalytic sequence of DNAzyme is flanked by 9 bases randomly
chosen and not specific for any MMP coding sequence. DNAzyme used in some of the
experiments was labeled with Oregon Green 488 C5-maleimide (Invitrogen, Carlsbad,
CA). Oregon Green 488 C5-maleimide was prepared in dimethyl sulfoxide to a stock
concentration of 25mM. The 5-hydroxyl terminus of the DNAzyme was labeled initially
with ATPS (Sigma, St. Louis, MO; 600 M) using T4 Polynucleotide kinase (New
England Biolabs, Ipswich, MA; 30U) followed by Oregon Green 488 maleimide (1mM)
at 37°C as suggested by manufacture. The labeled DNAzyme was then purified by
ethanol precipitation.
MMTV-PyMT Transgenic Mammary Tumor Model
The MMTV-PyMT transgenic mice express polyoma middle T antigen under the
control of mouse mammary tumor virus long terminal repeat [58]. The MMTV-PyMT
transgenic mouse model is a widely used preclinical model of estrogen and progesterone
receptor negative luminal breast cancer with well-defined stages of progression and
metastasis to lung [59, 60]. On a pure FVB/Nj strain background, all PyMT-positive
females exhibit an average tumor latency of 58 days after birth, independent of pregnancy
and will eventually develop mammary tumors in each of the ten mammary glands [61]
(Figure 2-1), the time of tumor onset varies among individual glands [60]. More than
90% of mice develop pulmonary metastasis by 100 days [62]. More importantly, the
mammary adenocarcinomas exhibit changes in biomarkers and expression patterns of
various MMPs similar to those observed in human breast cancer patients [59, 63-67].
Therefore, this model was chosen to ascertain the role of AM9D as a pharmacologic
inhibitor of MMP-9.
All animal experiments were conducted following approval by the University of
Tennessee Health Science Center Institutional Animal Care and Use Committee
(IACUC). FVB/Nj female mice were obtained from Jackson Laboratory (Bar Harbor,
ME) and crossed with PyMT positive FVB males. The offspring were genotyped by
real-time PCR on a Roche LC 480 LightCycler using the following primers and universal
probe library (UPL), probe #11 (Left primer: 5’ AACCCGAGTTCTCCAACAG 3; Right
primer: 5’ TCAGCAAC ACAAGGATTTC 3’) to identify MMTV-PyMT positive
females. Female mice were palpated once a week beginning at approximately 4 weeks of
age and palpable tumors were measured in two dimensions (longest diameter and shortest
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Figure 2-1.

Mouse mammary glands.

This is a basic diagram of the 10 mouse mammary glands and possible place of tumor
development in the MMTV-PyMT transgenic mouse model. Reprinted with permission
from Ward J. The Virtual Mouse Necropsy. Comparative Medicine Branch, NIAID, NIH.
Accessed March 25, 2010. http://icg.cpmc.columbia.edu/cattoretti/Protocol/
FilesInPdf/NCIVetp.pdf.
width) with digital calipers. Tumor volume was calculated using the formula, tumor
volume=(width2x length)/2. When each transgenic female developed at least three
palpable tumors of dimensions of 3 mm x 5 mm, which typically occurred at 8 weeks of
age, each tumor was injected intratumorally with 5 l PBS containing either 10 or 25 g
of AM9D or control DNAzyme using a Hamilton syringe mounted with a PT2, 26G
needle. Tumors identified at approximately 8 weeks of age were injected once per week
for a total of four weeks of therapy, and the site of intratumoral injection was varied to
ensure that all areas of the tumor were exposed to the AM9D or control DNAzyme.
Palpable mammary tumors that arose after the first intratumoral treatment in other
mammary glands of the same mice were left untreated. For each cohort, transgenic
females with a combined number of at least 9 tumors of comparable size were utilized
(AM9D, 10 ug, n= 2 mice, 9 mammary tumors; AM9D, 25 g, n=2 mice for a total of 10
mammary tumors and control DNAzyme, 10 or 25 g, n=4 mice, 12 mammary tumors).
The above experiment was repeated using 25 g of either AM9D (2 mice; 12 tumors) or
control DNAzyme (2 mice; 9 tumors) and the results were included in the calculation of
tumor endpoint weight reported.
Tumor growth was monitored weekly by caliper measurement. All animals were
euthanized one week after the last DNAzyme treatment (typically at 12 weeks of age). At
necropsy, tumors were removed, final tumor dimensions were measured by calipers, and
12

the tumor wet weight was determined. Tumors were then either flash frozen in liquid
nitrogen, or fixed in 4% paraformaldehyde overnight, followed by cryoprotection in 25%
sucrose for several days. Cryoprotected tumors were then washed with 0.1% PBS prior to
embedding in OCT compound and preparation of 8 micron frozen sections.
In Situ Hybridization
The presence of DNAzymes in mammary tumor slices was detected by in situ
hybridization using 5’ end fluorescently labeled anti-AM9D sense oligonucleotides
(5’-CGACCTCAAtcgttgtagctagccTGGcACCAC-3’) as a probe. The tumor slices were
incubated with 3 g of probe in hybridization buffer consisting of 25% formamide, 2X
SSC, 0.5 mg/ml Salmon Sperm DNA, 1X Denhart’s solution, 100 mM DTT and 10%
Dextran Sulfate, overnight at 42 ˚C. The slides were then washed twice with 2xSSC,
0.1% SDS for 5 min at RT followed by two washes with 2x SSC, 25% Formamide for 20
min at 45 ˚C, dried at RT, coverslipped and visualized by fluorescent and confocal
microscopy. The nucleus was visualized by addition of DAPI/anti-fade to each slide.
Histology and Immunohistochemistry
Mammary tumor sections were stained with hematoxylin and Eosin Y (H&E;
Fisher Scientific, Suwanee, GA). To block non-specific staining for
immunohistochemistry, sections were treated with 2% BSA in 1X PBS/0.2% Triton
X-100. Tumor vasculature was then visualized using rat anti-mouse CD31 antibody
(1:50) (BD Biosciences, San Jose, California) and Alexa Fluor-594 goat anti-rat IgG
(H+L) secondary antibody (Invitrogen, Carlsbad, CA). Stromal cells (myofibroblasts)
were detected by incubating the sections with anti- -smooth muscle actin antibody at
1:250 dilution (Sigma St. Louis, MO) overnight at 4°C and Alexa Fluor 488 goat
anti-mouse IgG2a (Invitrogen, Carlsbad, CA) secondary antibody at 1:500 dilution, for
1 h at room temperature. MMP-9 protein was detected using a rabbit anti-mouse MMP-9
antibody at a 1:200 dilution (Santa Cruz) overnight at 4°C followed by Alexa Fluor-594
goat anti-rabbit IgG antibody (1:500) at room temperature for 1h. CD31 and caspase-3
stained sections were blindly reviewed and grouped depending on their degree of red
(CD31) and green (caspase-3) positive staining. MMP-9 stained slides were quantified by
taking z-stack images and using image J. Digital images were captured using a Bio-Rad
Confocal Laser Scanning Microscope, using the Lasersharp 2000 software.
Statistical Analysis
All data are expressed as mean ± standard deviation or standard error. Data were
analyzed with SSPS software (SigmaStat version 2.03) using one-way analysis of
variance (ANOVA). Tumor growth over time among three groups was analyzed by
two-way ANOVA using Prism software (Graphpad version 4.0b). In all cases, p values
<0.05 were considered statistically significant.
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RESULTS
MMP-9 Is Expressed in Mammary Tumors of MMTV-PyMT Mice
To confirm the presence of MMP-9 protein in late-stage mammary carcinomas,
tumors were harvested from MMTV-PyMT transgenic females, at 12 weeks of age.
Tumor sections were stained with antibodies to both -smooth muscle actin (SMA), a
marker for stromal myofibroblasts, and MMP-9. Immunohistochemical analysis
demonstrated the presence of MMP-9 in stroma and in other areas, which could be tumor
epithelium, recruited immune cells, and endothelium (Figure 2-2).
DNAzyme In Vivo Stability
Prior to testing AM9D for its effect on mammary tumor growth, the in vivo
stability and cellular uptake of naked DNAzyme molecules was examined by
intratumorally injecting tumor-bearing MMTV-PyMT transgenic female mice with
fluorescently labeled AM9D (25 g) suspended in PBS. The animals were then
sacrificed at different time intervals post AM9D injection, and mammary tumors were
harvested, sectioned, and viewed under fluorescent microscope. Fluorescently labeled
oligonucleotides could be easily detected in a diffuse pattern within the tumor for up to
14 days after injection (Figure 2-3). Moreover, the AM9D could also be detected in
adjacent, non-injected mammary tumors of the same mouse (Figure 2-3b), indicating a
wide distribution pattern than might be expected from intratumoral injection. Therefore,
the DNAzymes are stable in vivo and can efficiently distribute within the injected tumor
and to a nearby non-injected tumor.

Figure 2-2.

MMP-9 in MMTV-PyMT mice mammary tumors.

Immunohistochemical staining for MMP-9 in mammary tumor sections. Tumors were
resected from MMTV-PyMT mice and double stained with antibodies to -smooth
muscle actin to detect stromal cells (a) and MMP-9 (b). When channels were merged (c),
these data show that MMP-9 is present in both stromal cells and in other areas.
Magnification 200X. Scale bar in (c) is equivalent to 100 m.
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Figure 2-3.

Stability of DNAzyme in mammary tumors.

Mammary tumors were injected as described in the methods with fluorescently labeled
AM9D and resected at either (a) 7 days, (b) 10 days, or (c) 14 days post-injection. (e)
Mammary tumor injected with unlabeled DNAzyme was used as a negative control. Of
note, (d) DNAzyme injected into the 2R tumor of a mouse was found to be distributed to
an adjacent, non-injected mammary tumor, 3R, which had emerged after injections were
first initiated. Scale bar in (d) is equivalent to 100 m.
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Effect of AM9D Treatment on Final Tumor Load
The efficacy of AM9D to reduce breast tumor volume in MMTV-PyMT
transgenic mice was tested by directly injecting two concentrations (10 g or 25 g) of
AM9D or control DNAzyme into mammary tumors of transgenic females bearing at least
3 tumors per mouse, each at an early palpable size (~3 mm x 5 mm), once a week for 4
weeks. Tumor palpations were performed weekly to determine changes in tumor volume
over time. The rate of tumor growth in tumors treated with 25 g of AM9D (n=12
tumors) was slower than that of the untreated tumors (n=7 tumors) or DNAzyme control
treated (n=9 tumors) tumors (Figure 2-4a). Although, the observed difference in tumor
growth over time in control and AM9D treated groups was not significant at early stage
of growth (8-11 weeks of age; 2-way ANOVA, p>0.05), the difference was statistically
significant at 12 weeks of age (Figure 2-4), the study endpoint. The p values obtained for
AM9D vs. control DNAzyme treated and untreated tumors were p<0.001 and p<0.01,
respectively. The final tumor volume of AM9D treated tumors was significantly reduced
compared to that of the control DNAzyme treated tumors (Figure 2-4b). In fact,
administration of AM9D at 10 g was sufficient to reduce the size of the tumor by
39.5%, which increased to 50.1% when 25 g of AM9D was utilized (p<0.01 for
statistical comparison of control to 10 g and to 25 g, one-way ANOVA).
Immunohistochemical analysis of the mammary tumors (Figure 2-5) confirmed
that AM9D treatment successfully down-regulated MMP-9 protein expression. As
shown in Figure 2-5b, AM9D treatment reduced MMP-9 expression by 66 ± 11% in
tumor compared to the control DNAzyme treatment (Figure 2-5a). In addition, in situ
hybridization of the tumor tissue slices demonstrated the presence of DNAzyme in tumor
and the surrounding tissue (Figure 2-6). Taken together, these data show that AM9D
efficiently decreases MMP-9 expression in tumors, which is responsible for the observed
anti-tumor effects.
Effect of AM9D on Angiogenesis and Apoptosis
MMP-9 has been shown to play a role in tumor progression through increase of
bioavailability of VEGF and other factors that promote angiogenesis [30]. To determine
the mechanism of tumor volume reduction by AM9D, the tumor slices were stained for
CD-31 and for caspase-3 to assess the effect of AM9D on angiogenesis and apoptosis,
respectively. AM9D treatment substantially reduced the number of blood vessels in the
tumor as demonstrated by the lack of robust CD-31 immunostaining in the AM9D treated
group (Figure 2-7c) versus untreated (Figure 2-7a) or the control DNAzyme treated
(Figure 2-7b) groups. These data suggest that anti-angiogenic effect of AM9D delays
tumor growth over time and tumor volume at our study endpoint. Moreover, our data also
indicate that AM9D induces apoptosis in the tumor. This is based on the observation that
only AM9D treated tumors contain a large number of caspase-3 positive cells
(Figure 2-8). Therefore, AM9D therapy can simultaneously induce tumor cell apoptosis
and decrease stromal cell neo-angiogenesis.
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Figure 2-4.
volume.

Effect of AM9D on the rate of tumor growth and final mean tumor

(a) AM9D-treated tumors () grew at a slower rate than either untreated tumors (no
injections, ) or tumors treated with control DNAzyme (). The difference between
control DNAzyme treated and untreated tumors is not significant at 8-11 weeks of age
(p>0.05), but is statistically significant at 12 weeks of age (p<0.05), the study endpoint.
(b) Weekly intratumoral treatment of transgenic mice with 10 g (n=9 tumors) or 25 g
AM9D (n=21 tumors) per tumor reduced mean tumor burden by 39.5% or 50.1%,
respectively, when compared to tumors treated with control DNAzyme (n=24 tumors)
(p<0.01 ANOVA).
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Figure 2-5. Effect of AM9D on MMP-9 protein expression in MMTV-PyMT
mammary tumors.
Mammary tumors treated with either 25 g control DNAzyme or AM9D were stained
with an anti-MMP-9 antibody. Mammary tumors treated with (b) AM9D for 4 weeks
showed lower MMP-9 staining compared to (a) those treated with 25 g control
DNAzyme for 4 weeks. Images are shown at 200x magnification; scale bar is equivalent
to 100 m.

Figure 2-6.

Fluorescent in situ hybridization.

In situ hybridization performed on 25 g AM9D-treated mammary tumors at study
endpoint. (a) Green signal indicates the presence of AM9D DNAzyme (arrows) and (b)
DAPI was used to detect cell nuclei. (c) Images (a) and (b) merged. Magnification 400X.
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Figure 2-7.

AM9D reduces tumor vasculature.

Immunohistochemical staining for CD31 (red) to detect the vasculature in mammary
tumors harvested from mice treated with 25 g of AM9D (c and e) or control DNAzyme
(b and d). A subset of sections was also counterstained with DAPI (d and e). Untreated
tumors (a) and tumors treated with control DNAzyme (b and d) contained more blood
vessels than did tumors treated with AM9D (c and e). Images are shown at 200x (a-c) or
400x (d and e) magnification. Scale bar is equivalent to 100 m (a-c) and 50 m (d and
e).

Figure 2-8.

AM9D induces apoptosis.

Immunohistochemical staining of mammary tumors harvested from mice treated for four
weeks with 25 g (a) control DNAzyme or (b) AM9D for caspase-3 indicate AM9D
treatment (b) induces apoptosis in mammary tumors. Caspase 3 staining is shown in
green and nuclei are stained blue with DAPI. Very few caspase-3 positive cells (green)
were detected in tumors treated with control DNAzyme (a) compared to AM9D-treated
tumors (b), where large regions stained positive for caspase-3. Scale bar is equivalent to
100 m.
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DISCUSSION
In this study, we show for the first time, that the down regulation of MMP-9 in
mammary tumors by a novel anti-MMP-9 DNAzyme molecule results in a significant
reduction in final tumor volume in the MMTV-PyMT transgenic mouse model of breast
cancer. Down regulation of MMP-9 by AM9D was accompanied by a decrease in
MMP-9 expression, decreased angiogenesis and increased apoptosis. Moreover, these
effects were accomplished by intratumoral injection of naked DNAzyme without the use
of any carriers. Together, these data indicate that inhibition of MMP-9 expression by
DNAzyme has potential as a novel therapeutic modality to decrease growth and invasion
of carcinoma cells in the clinical setting.
It is known that MMP-9 plays a key role in angiogenesis by releasing VEGF [30]
and that its down regulation induces apoptosis by stimulating ERK pathway [32]. Martin
et al. [68] have demonstrated that spontaneous lung metastases decreased by 80% in
MMTV-PyMT MMP-9 null mice compared to MMTV-PyMT MMP-9 wild type mice. In
addition, the lung tumors developed in MMTV-PyMT MMP-9 wild type mice are larger
in size and are more highly vascular compared to those tumors that developed in
MMTV-PyMT MMP-9 null mice. Thus, the data presented here is consistent with the
above studies and demonstrate that down regulation of MMP-9 by AM9D also affects
tumor growth via inhibiting angiogenesis and inducing apoptosis (Figures 2-7 and 2-8) as
demonstrated by lack of CD31 staining and the enhanced presence of caspase3 in AM9D
treated tumors.
Our results are consistent with those of Almholt, et al. [67] which showed that the
broad-spectrum MMP inhibitor Galardin/GM6001, significantly reduced primary
mammary tumor growth by 50% and reduced lung metastasis by more than 100-fold in
the MMTV-PyMT model. However, contrary to broad-spectrum MMP inhibitors,
including GM6001, AM9D treatment specifically down regulates MMP-9 without
affecting the expression of other members of the MMP family (Figure 1-3b and 1-3c). As
demonstrated by the extent of cytoxicity of broad spectrum MMP inhibitors in prior
clinical trials [41, 46, 47], total inhibition of MMPs is not practical, since various MMPs
can exert both pro-tumorigenic and anti-tumorigenic properties [17]. In addition, MMPs
are critical for normal physiological processes, such as bone growth and remodeling,
ovulation, and wound healing [19]. Further, in comparison with GM6001 [67], the
intratumoral injection of AM9D not only reduced the required frequency of therapy; it
was equally efficient in reducing final tumor size. Once weekly, intratumoral injections
of 25 g AM9D (1.25 mg/kg) was sufficient to reduce the size of these spontaneously
developed tumors by 50% as compared to the 51% tumor reduction observed following
daily administration of 100 mg/kg of GM6001. Thus, the high degree of specificity for
targeting MMPs, the lack of in vivo toxicity and the increased efficacy of AM9D as
compared to broad spectrum inhibitors should enhance the clinical response of solid
tumors, including breast tumors, while evading the serious side effects experienced with
systemic therapy based on broad-spectrum MMP inhibitors.
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CHAPTER 3.

DISTRIBUTION, CLEARANCE, AND CYTOTOXICITY OF
DNAZYME
INTRODUCTION

Enzymatic DNA molecules have been used recently in cell based assays and
preclinical animal studies to treat various cancers. We have shown that intratumoral
injections of anti-MMP-9 DNAzyme (AM9D) reduced mammary tumor burden in
MMTV-PyMT transgenic mice by 50% (Chapter 2). As described previously,
DNAzymes designed to specifically target Aurora kinase A inhibited growth of human
prostate cancer in vivo [52]. A DNAzyme targeting VEGF2 mRNA led to a 75%
reduction in tumor size compared to saline treated control [53] and treatment of
MDA-MB-231 xenograft solid tumor model with an EGR-1 mRNA specific DNAzyme
(DzF) resulted in inhibition of tumor growth compared to saline treated control [69].
However, all of these preclinical studies of tumor growth were conducted via
intratumoral injections. While intratumoral injections can illustrate the promise of
DNAzymes relative to target specificity and therapeutic potential, it is impracticable for
clinical trials in humans. Thus, successful systemic application of DNAzymes in
pathophysiological and therapeutic studies requires prior demonstration of significant
uptake of DNAzyme by the target tissues. Moreover, to optimize DNAzyme regimens,
tissue distribution and clearance must also be studied in vivo.
In this body of work, we have shown, for the first time, that naked AM9D is safe
when administered systemically to healthy FVB mice and distributes to all organs of
healthy mice and the Mouse Mammary Tumor Virus-polyoma middle T antigen
(MMTV-PyMT) transgenic mouse model of breast cancer.
MATERIALS AND METHODS
Synthesis of 35S-radiolabeled Oligonucleotides
The DNAzyme molecules were labeled at the 5’ end using ATP- 35S (Perkin
Elmer, Waltham, MA) and T4 polynucleotide kinase (Promega, Madison, WI). The
35
S-labeled DNAzyme ([35S]-DNAzyme) was then purified using a centri-10 column
(Applied Biosystems, Carlsbad, CA). [35S]-DNAzyme was dissolved in sterile Phosphate
Buffered Saline (PBS). The concentration of the solution was adjusted so that 100 l
administered to 20g mice resulted in a dose of 10 mg/kg of body weight (specific activity,
0.275 mci/kg). [35S]-DNAzyme was mixed with unlabeled DNAzyme to obtain the
desired concentration.
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Animal Experiments
All animal studies were done in accordance with the guidelines established by the
Animal Care and Use Committee at The University of Tennessee Health Science Center.
Twenty-three 8 week-old female FVB mice weighing 20-25 g and 19 MMTV-PyMT
transgenic mice (FVB strain) bearing mammary tumors of various sizes and weighing
17-22 g were used in this study. MMTV-PyMT transgenic mice develop tumors in 6-8
weeks of age. Mice bearing a range of early (<500 mm3) and late stage (>750 mm3)
tumors were used.
Systemic Distribution
Normal Mice. [35S]-DNAzyme, 100 l (10 mg/kg; 0.275 mci/kg) in PBS was
administered into 23 healthy anesthetized mice via tail vein injection. Three animals
were placed in metabolism cages, immediately following injection, for 7 days (168 h).
The urine and feces were collected daily for total radioactivity determination from each
of the three animals. All samples were collected and stored at -80 ˚C until analysis. The
remaining 20 mice were divided into 5 groups of 4 animals each and at 2, 6, 24, 48, and
72 h following intravenous administration of [35S]-DNAzyme, one group of animals was
sacrificed and liver, heart, lung, kidney, and spleen were removed for determination of
total radioactivity. This experiment was repeated using 6 mice divided into 2 groups of 3
mice each. At 2 and 6 h following intravenous administration of [35S]-DNAzyme, one
group of animals was sacrificed and liver, heart, lung, kidney, spleen, intestines, brain,
pancreas, and stomach were removed for determination of total radioactivity.
Immediately prior to sacrifice, blood samples (0.5-1 ml) were collected from anesthetized
mice via the retro-orbital vein.
MMTV-PyMT Mice. DNAzyme was administered as above into 19 tumor
bearing mice and these were divided into 5 groups of 3 animals each and one group of 4
animals. At 2, 4, 8, 24, 48, and 72 h following [35S]-DNAzyme administration, one
group of animal was sacrificed. Tumor volumes were measured using calipers during the
experiments, and after excision, wet weights were recorded. Tumors exceeding 1.37g
were highly heterogeneous (i.e. necrotic areas and mixture of tumor consistency) and thus
were not included in any statistical analysis of mammary tumors. Heart, lung, kidney,
liver, spleen, and blood samples were removed for determination of total radioactivity.
Radioactive Sample Analysis
Organs were solubilized in at least 1 ml SOLVABLE according to manufacturer’s
instruction (Perkin Elmer) and incubated overnight at 50 ˚C. Endogenous peroxidase
activity was quenched with 10mM EDTA and 6% hydrogen peroxide for 1 h at 50 ˚C.
Blood samples were collected from each mouse and 200 l of each sample was incubated
with 1 ml SOLVABLE at 50 ˚C for 1 h. The endogenous peroxidase activity in blood was
quenched with EDTA and hydrogen peroxide, as above. Approximately 10 ml of
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scintillation cocktail fluid was added to each sample and tissue radioactivity was
measured using a Packard Tri-Carb 2900CA liquid scintillation analyzer. Counts per
minute obtained from each sample were converted to microgram of DNAzyme
equivalents and presented as the total g DNAzyme per either weight or volume of
tissue, blood, urine, or fecal output. Initial and final rates of clearance were calculated
based on the slope of the line obtained from plotting g DNAzyme per gram of tissue (ml
blood) as a function of time (initial: 2-6 h for normal mice and 2-8 h for MMTV-PyMT
mice, final: 24-72 h). All data were expressed as mean ± standard deviation of mean.
The quenching effect of tissue on radioactive count was tested by adding appropriate
amounts of [35S]- DNAzyme to scintillation vials containing solubilized normal organs.
No significant tissue quenching effect was observed.
Cytotoxicity
Healthy mice were intravenously injected with PBS or various concentrations
(10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) of either AM9D or Scrambled
DNAzyme. Five mice per dosage for a total of 35 mice were used. The mice were
sacrificed 7 days after DNAzyme administration. Following dosing, animals were
observed daily for signs of toxicity including trouble grooming, lack of food
consumption, and any other signs of lethargy; none was observed. At necropsy, liver,
heart, lung, kidney, and spleen were collected and fixed in 4% paraformaldehyde,
impregnated with 25% sucrose that acts as a cryoprotectant, and were processed for
histopathological evaluation (standard light microscopic examination of hematoxylin and
eosin-stained tissue slides).
RESULTS
Kinetics of DNAzyme in Normal Mice
The systemic distribution of DNAzyme in mice and its rate of clearance were
determined by injecting naked [35S]-AM9D (10 mg/kg) in PBS via tail vein into healthy
FVB mice and the amount of radioactivity present in blood and different organs was
measured as a function of time. Figure 3-1a illustrates the tissue/blood distribution time
profile of DNAzyme in mice. AM9D injected via tail vein in mice is distributed to all
major organs; liver, heart, spleen, kidney, and lungs. Two hours after DNAzyme
injection, approximately 10% of the total DNAzyme was found in major organs
(Table 3-1). The order of percentage accumulation was: blood>liver>kidney>lung>
spleen>heart. Blood contained a majority of DNAzyme with 6.3% of the total DNAzyme
in the first 2 h and reduced to 2.1% after 6 h (Table 3-1). Studies revealed 1.8%, 1.1%
and 0.4% of total DNAzyme injected was delivered to liver, kidney, and lung,
respectively. Finally, spleen and heart contained 0.21% and 0.2% of total DNAzyme in
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Figure 3-1.
mice.

Distribution and elimination profile of [35S]-DNAzyme in normal

(a) Distribution profile for [35S]-DNAzyme in tissue and blood. The tissue concentration
of [35S]-DNAzyme derived radioactivity is based on g equivalent DNAzyme/g of organ
and is the mean (+/- stdev) of 3-4 mice for each tissue. Blood concentrations are the mean
values from all samples collected at each time point throughout the experiment. The
DNAzyme blood concentration was first corrected for total blood in mouse based on the
animal’s weight and a mean of blood volume of 79 l/g body weight. Then, for
calculation of g DNAzyme/g of blood, 1 ml blood was assumed to be equal to 1 g. (b)
Elimination profile for [35S]-DNAzyme. The urine and fecal concentrations are mean
values calculated for the total output from three mice each day for a total of 7 days.

24

Table 3-1.
Tissue distribution of [35S]-DNAzyme in normal mice presented in
average percentage of total DNAzyme.
Tissue

2h

6h

24 h

48 h

72 h

7 days

Liver

2.198
(1.59-2.55)

1.375
(.94-2.2)

0.281
(.16-.46)

0.141
(.12-.16)

0.108
(.05-.14)

0.185
(.09-.31)

Heart

0.205
(.15-.26)

0.144
(.06-.22)

0.042
(.03-.05)

0.022
(.01-.02)

0.016
(.01-.03)

0.005
(.003-.007)

Spleen

0.215
(.17-.26)

0.08
(.05-.14)

0.029
(.02-.04)

0.02
(.01-.02)

0.021
(.017-.023)

0.008
(.005-.01)

Kidney

1.132
(.90-1.5)

0.575
(.33-.84)

0.209
(.17-.24)

0.138
(.11-.16)

0.109
(.09-.12)

0.048
(.03-.07)

Lung

0.366
(.28-.51)

0.216
(.15-.30)

0.061
(.04-.07)

0.043
(.04-.05)

0.033
(.02-.04)

0.01
(.008-.01)

Blood

6.264
(3.0-11.4)

2.103
(.96-3.3)

0.305
(.16-.42)

0.143
(.08-.17)

0.102
(.09-.13)

0.068
(.05-.08)

Numbers in parentheses give the range of data.
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2 h post injection, respectively. The majority of the DNAzyme was cleared from these
organs within the first 24 h. Thirty-one percent of the delivered dosage of
[35S]-DNAzyme was cleared from the system via feces and urine over a period of 72 h.
This experiment was repeated for time points 2 and 6 hours after DNAzyme
injections to assess distribution of DNAzyme to the following additional organs: brain,
pancreas, stomach, and intestines. Similar to the above experiments, 100 l of
[35S]-DNAzyme (10 mg/kg; 0.275 mci/kg) in PBS was administered into 6 healthy
anesthetized mice via tail vein injection. The 6 mice were divided into 2 groups of 3
animals each and at 2 and 6h following intravenous administration of [35S]-DNAzyme,
one group of animals was sacrificed and liver, heart, lung, kidney, spleen, intestines,
brain, pancreas, and stomach were removed for determination of total radioactivity
(Figure 3-2). As shown in Figure 3-2, 2 and 6 h after injection, in addition to the organs
previously described, DNAzyme can be found in brain (0.312 g and 0.248 g
DNAzyme/g), pancreas (1.147 and 1.0 g DNAzyme/g), intestines (11.11 and 11.42 g
DNAzyme/g), and stomach (11.92 and 7.41 g DNAzyme/g). This data demonstrates that
DNAzyme molecule is capable of passing the blood brain barrier and suggests that it can
be used as a therapeutic agent against brain tumors, as well as tumors which affect the
pancreas, liver, and stomach (gastrointestinal stromal tumor).
The rate of initial clearance (from 2-6 h) and final clearance (from 24-72 h) of
DNAzyme from different organs were calculated based on the amount of DNAzyme
remaining in tissues as a function of time (Table 3-2). The rate of initial clearance of
DNAzyme from blood was faster than kidney followed by spleen>liver>heartlung

Figure 3-2.
mice.

Distribution profile of [35S]-DNAzyme in additional organs of normal

The tissue concentration of [35S]-DNAzyme derived radioactivity is based on g
equivalent DNAzyme/g of organ and is the mean (+/- stdev) of organs isolated from 3
mice.
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Table 3-2.

Liver

Initial clearancea
g DNAzyme/g tissue/h
0.281

Final clearanceb
g DNAzyme/g tissue/h
0.0039

Heart

0.149

0.0052

Spleen

0.442

0.0023

Kidney

0.495

0.0074

Lung

0.143

0.0022

Blood

5.202

0.0123

Tissue

a

Rate of [35S]-DNAzyme initial and final clearance in normal mice.

Initial clearance is between 2-6 h.
Final clearance is between 24-72h.

b

(Table 3-2). The rates of initial and final clearance of DNAzyme from kidney were 0.495
g DNAzyme/g of tissue/h and 0.0074 g DNAzyme/g of tissue/h, respectively. The rate
of initial clearance of AM9D from heart and lung are equivalent, however, DNAzyme is
retained in lung longer as its rate of final clearance in lung is approximately 2-fold slower
than that of the heart (Table 3-2).
Fecal excretion represented the major pathway of DNAzyme elimination
(Figure 3-1b). The amount of DNAzyme excreted in feces (32%) is 3-fold greater than
the amount released from urine (11%) over the 7-day period. As expected, DNAzyme
excretion was time-dependent with the majority being eliminated in the first 72 h.
Kinetics of DNAzyme in Mammary Tumor bearing Mice
Female MMTV-PyMT transgenic mice bearing early to late stage mammary
tumors were used to test the distribution of DNAzyme to mammary tumors. Naked
[35S]-DNAzyme in PBS was administered to tumor bearing animals via tail vein
injections, animals were then sacrificed at different times and the amount of
[35S]-DNAzyme present in different organs, blood, and mammary tumors were
determined as a function of time (Figure 3-3a and b). The order of percentages
of [35S]-DNAzyme accumulation in different organs of MMTV-PyMT mice was
mammary tumor>liverblood>kidney>spleen>lung>heart. [35S]-DNAzyme concentration
in the mammary glands was markedly higher than in other tissues. In these mice, 4.1%
of the total injected DNAzyme was accumulated in the mammary tumors in 2 h
(Table 3-3). Mammary tumors of transgenic mice were of varying sizes and the amount
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Figure 3-3.

Distribution profile of [35S]-DNAzyme in MMTV-PyMT mice.

(a) Transgenic mice developed on average 7 mammary tumors per mouse and the mean
value of tumor for 3-4 mice were calculated. Small and medium size tumors displayed
different accumulation and clearance profiles. For this reason, tumors weighing less than
1.37 g were divided into two categories, small (<0.7 g) and medium (0.7 g, 1.37 g).
Tumors exceeding 1.37 g were excluded. (b) The tissue concentration of [35S]-DNAzyme
derived radioactivity is based on g equivalent DNAzyme/g of organ and is the mean of
3-4 mice for each tissue. The blood samples were collected from all mice. The DNAzyme
blood concentration was first corrected for total blood in mouse based on the animal’s
weight and a mean of blood volume of 79 l/g body weight. Then, for calculation of g
DNAzyme/g of blood, 1 ml blood was assumed to be equal to 1 g.

28

Table 3-3.
DNAzyme.

Tissue distribution of [35S]-DNAzyme in MMTV-PyMT mice presented in average percentagea of total
Tissue

2h

Liver

3.89
(2.7-5.76)

Heart

4h

8h

24 h

48 h

72 h

3.31
1.72
(3.2-3.5) (1.5-1.9)

0.72
(.47-1.0)

0.46
(.419-.529)

0.31
(.215-.355)

0.33
(.27-.41)

0.24
(.17-.30)

0.17
(.11-.25)

0.05
(.03-.07)

0.018
(.012-.022)

0.009
(.007-.013)

Spleen

0.54
(.27-.88)

0.4
(.35-.46)

0.26
(.21-.32)

0.13
(.08-.24)

0.03
(.029-.038)

0.025
(.019-.028)

Kidney

1.27
(.83-1.9)

1.1
(.93-1.3)

0.63
(.54-.69)

0.3
(.03-.55)

0.15
(.13-.16)

0.14
(.011-.016)

Lung

0.38
(.18-.77)

0.28
(.18-.39)

0.184
(.1-.3)

0.07
(.04-.1)

0.051
(.046-.055)

0.029
(.022-.032)

Mammary
Tumor b

4.1
(.06-9.2)

5.5
(.1-8.5)

5.2
(3.3-7.2)

1.3
(0.5-2.3)

0.049
(.011-.105)

0.038
(.020-.059)

Blood

3.52
(3.4-3.8)

2.97
(2.4-3.5)

1.64
(1.5-1.7)

0.69
(.52-.86)

0.216
(.168-.274)

0.115
(.080-.166)

a

Numbers in parentheses give the range of data.
Tumors larger than 1.37 g were excluded from calculations. Data range in mammary tumors is attributed to range of tumor sizes.
The large range of data in organs, in some cases, is attributed to technical error of injection.
b
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of DNAzyme accumulated in mammary tumors was proportional to the weight of the
tumor burden (Figure 3-4).
Interestingly, the accumulated DNAzyme in the mammary tumor is initially
cleared at a slower rate compared to the other organs, with rate of initial clearance (2-8 h
post DNAzyme injection) of 0.068 g DNAzyme/g tissue/h (Table 3-4). The mammary
tumors characterized as small tumors (<0.7 g) continue accumulating DNAzyme 2-4 h
post injection (Figure 3-3a). This corresponds with the initial clearance of DNAzyme
from blood 2-4 h post DNAzyme injection (Figure 3-3b). Similar to DNAzyme
distribution in normal mice, the percentages of the total DNAzyme accumulated in blood,
liver, kidney, lung, spleen, and heart, 2 h post DNAzyme injection, was 3.5%, 3.9%,
1.3%, 0.4%, 0.5% and 0.3%, respectively (Table 3-3). However, the rate of initial
clearance of DNAzyme from spleen was slower than blood but faster than any other
organs tested followed by LiverKidney>Heart>Lung>Mammary tumors (Table 3-4).
The majority of the DNAzyme was eliminated from the organs and blood within the first
24 h (Figure 3-3b). The rate of initial clearance from liver and kidney was found to be the
same (4.3 g DNAzyme/g tissue/h) during the first 8 h of administration and slightly
increased in kidney between 24-72 h. In heart, the rate of clearance in 2-8 h (initial) and
24-72 h (final) post administration was 2 and 3.4-folds faster than that in lung,
respectively (Table 3-4).
Cytotoxicity of Intravenous Injection of AM9D in Healthy Mice
Safety of DNAzyme delivered intravenously in healthy FVB mice was
determined using single injection of escalating concentrations of AM9D or control
DNAzyme (10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) in PBS. PBS was used as
a control. Seven days post DNAzyme injection, mice were sacrificed and liver, spleen,
lung, heart, and kidney were isolated and analyzed for cytotoxicity by H&E staining
(Figure 3-5). All tissues were evaluated (in a blinded manner) for evidence of capillary
leakage, acute cellular damage including necrosis or apoptosis, acute inflammation and
mitotic activity by a pathologist. No evidence of acute cytotoxicity, mitogenesis, cell
death, local or widespread, was observed in the organs examined.
DISCUSSION
These results indicate that DNAzyme oligonucleotides could be delivered
intravenously to all organs without the use of lipids or other carrier molecules, as naked
DNAzyme was injected, and that the [35S]-AM9D was present in various organs
including mammary tumor tissues and organs of high incidence for metastasis (i.e. lung).
In addition, mammary tumors can take up the DNAzyme faster and retain it longer than
any other organs. Together, these data suggest that DNAzymes can be useful as a
therapeutic agent to treat human patients with breast cancer or any other solid tumors.
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Figure 3-4.

Distribution of [35S]-DNAzyme in MMTV-PyMT mammary tumors.

Total tumor burden was measured in grams and the total g DNAzyme found in tumors
were calculated. DNAzyme injected into mice bearing tumors of varying sizes show a
proportional correlation between tumor size (all tumors combined per mouse) and
DNAzyme distribution (Y=1.4045x-0.4159, R2=0.7764).
Table 3-4.
Rate of [35S]-DNAzyme initial and final clearance in mice with
mammary tumors.

Liver

Initial clearancea
g DNAzyme/g tissue/h
0.434

Final clearanceb
g DNAzyme/g tissue/h
0.0052

Heart

0.277

0.0082

Spleen

0.653

0.0278

Kidney

0.426

0.0063

Lung

0.134

0.0024

Mammary
Tumorc

0.068

0.0128

Blood

1.507

0.0569

Tissue

a

Initial clearance is between 2-8 h.
Final clearance is between 24-72 h.
c
Tumors larger than 1.37 g were excluded from calculations.
b
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Figure 3-5. Pathology of organs from mice injected with AM9D, control
DNAzyme, or PBS.
Mice injected with PBS, or various concentrations of control or AM9D showed no
difference in organ pathology. The tissues displayed were extracted from mice that
received the highest dose (75 mg/kg of AM9D and control DNAzyme; 400x
magnification).
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Recently, DNAzymes have emerged as novel, highly selective inhibitors of gene
expression. Although they have yet to be used in clinical trials, reports of studies
demonstrating the efficacy of DNAzyme based cancer therapies are beginning to emerge
[50]. However, thus far, all of the preclinical studies testing the effect of DNAzyme on
tumor growth were via intratumoral or subcutaneous injections. In spite of the fact that
tumor growth is an important factor in cancer progression, metastasis is ultimately the
determining factor for cancer survival for many types of cancer [70-72]. Thus, while
intratumoral injections can show promise as to the DNAzymes specificity to its target and
future therapeutic capabilities, it is not feasible in humans. To advance the therapeutic
potential of DNAzyme toward clinical trial, it is necessary to design an anti-metastatic
DNAzyme and demonstrate its anti-metastatic potential based on its systemic
distribution, safety and efficacy.
Expression of MMP-9, by tumor and stroma cells has been shown in breast cancer
patients [73] and is one of the most important factors for metastatic behavior of tumor
cells [23, 54, 74]. MMP-9 degrades type IV collagen, one of the most abundant collagens
in the ECM [11, 75] and is involved in cell proliferation, angiogenesis, and apoptosis [9,
10, 30]. Increasing evidence suggests that MMPs contribute to the formation of a
microenvironment that promotes tumor growth during early stages of tumorigenesis.
Our observation that AM9D treatment decreased MMP-9 production (Figure 1-3c and
2-4) and reduced invasive behavior of human MDA-MB-231 cells (Figure 1-3d)
suggested that AM9D has a great potential as an anti tumorigenic/metastatic agent. Thus,
to utilize anti-MMP-9 DNAzyme (AM9D) as a therapeutic agent in breast cancer
preclinical and clinical studies, healthy and MMTV-PyMT transgenic mouse model
bearing early to late stage tumors were used to test the distribution of AM9D to different
organs and mammary tumors. The order of percentage accumulation of DNAzyme in
healthy mice in different organs was: blood>liver>kidney>lung>spleen>heart. In addition
to these organs, [35S]-DNAzyme was also distributed to brain, intestines, stomach, and
pancreas (Figure 3-2). Approximately, 43% of the delivered dosage of [35S]-DNAzyme
was cleared from the system via feces and urine over a period of 72 h (Figure 3-1b). This
data is consistent with Agrawal et al.’s observation that 40% of intravenously
administered anti-sense phosphorothioate oligonucleotides complementary to HIV RNA
in mice, is excreted in urine and 16% in feces within the first 48 h [76]. Contrary to these
data, however, we observed a higher excretion of DNAzyme in feces than in urine
(Figure 3-1b).
Interestingly, when [35S]-DNAzyme was administered to MMTV-PyMT
transgenic mice the amount of DNAzyme accumulated in mammary tumors 2 h post
injection was 0.6% and 0.2% higher than in either blood or liver, respectively, and its rate
of initial clearance from mammary tissue was slower than the other organs (Tables 3-3
and 3-4). The amount of DNAzyme accumulated in mammary tumors was proportional
to the tumor burden (Figure 3-4), suggesting a favorable therapeutic outcome. This is
expected considering that mammary tumors can be highly vascularized [77].
DNAzyme administered systemically is safe and at 75 mg/kg of body weight
caused no observable mortality or organ toxicity in mice. Pathological studies did not
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reveal any evidence of acute toxicity, mitogenesis, or cell death, local or widespread in
any organs examined (Figure 3-5), contrary to those described for other oligonucleotides
[78]. Several investigators have reported hepatocyte toxicity and necrosis [76, 78] and
renal tubular structural perturbations [76] with oligonucleotide administration as low as
20 mg/kg [78] and as high as 30 mg/kg/day over 14 days (total 420 mg/kg) [76]. This
however, was not observed in this study. It should be noted that the delivered dosage of
AM9D for this study (75 mg/kg) was much higher than those used in the other DNAzyme
studies [78], however, lower than some studies which showed hepatocyte toxicity [76].
In conclusion, systemic distribution and safety/toxicity studies revealed that the
naked AM9D is non-toxic when systemically administered, and has favorable
pharmacological properties with respect to intravenous administration and tissue
distribution. Most importantly, mammary tumors can take up the naked DNAzyme. The
amount of DNAzyme accumulates in the mammary gland is higher and its rate of
clearance is slower than any other organs tested. These factors may permit the
development of DNAzyme as a cancer therapeutic agent with much improved toxicity
profiles as compared with conventional drugs.
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CHAPTER 4.

AM9D TREATMENT OF EXPERIMENTAL METASTASIS
INTRODUCTION

The role of MMP-9 in cancer metastasis has been widely researched. The
treatment of DU145 prostate cancer cells with curcumin, an anti-metastatic derivative
from tumeric, has been shown to decrease the levels of MMP-2 and -9 and lead to a
decrease in tumor volume [79]. Curcumin treatment has also been shown to alter the
invasive and metastatic properties of MCF10A human breast epithelial cells [80] and
decrease metastasis to lung in a human breast cancer xenograft model [81] by decreasing
the levels of MMP-9 and COX-2. According to Eiseler, et al., highly invasive breast
cancer human tissue samples, regardless of stage and progesterone or estrogen
dependence, were shown to have reduced Protein Kinase D1 (PKD1) expression in
greater than 95% of the tumor samples compared to normal breast tissue [82].
Furthermore, the invasiveness of MDA-MB-231 cells was reduced by the re-expression
of PKD1, which was shown to negatively regulate MMP-9, the mainly expressed MMP
in MDA-MB-231 cells. [82]. Thus, PKD1 regulates breast cancer cell invasion through
regulation of the expression of MMP-9. Furthermore, Chen et al. provided evidence that
the presence of increased levels of MMP-9 in integrin alpha1-null mice enhanced the
number of tumors on lung but these tumors were smaller compared to lung tumors in WT
counterparts [83]. They also showed that inhibition of MMP-9 by doxycyclin in these
alpha1-null mice led to reduced number of lung colonies but bigger tumors were
observed. This was because reduced MMP-9 plasma levels led to decreased generation of
angiostatin, an anti-angiogenic molecule. Thus, while an MMP-9 inhibitor may be useful
in treating tumor cell migration, invasion, and metastasis it may adversely increase
growth and vascularization of tumors intravenously introduced to lung.
In previous Chapters of this body of work we have shown that, in accordance with
the findings of Eiseler, et al. [82], down-regulation of MMP-9 by AM9D decreases the
invasive potential of MDA-MB-231 human breast cancer cells. We have also shown the
presence of MMP-9 in MMTV-PyMT mammary tumors (Figure 2-2) and presented
evidence that MMP-9 expression is significantly lower in AM9D treated tumors
compared to control (Figure 2-5), leading to a reduction in final tumor load (Figure 2-4).
Furthermore, AM9D when injected via the tail vein of normal and MMTV-PyMT mice
was shown to be distributed to all major organs including lung and was tested to be safe
up to 75 mg/kg of body weight (1500 g/100 l of PBS).
MMP-9 is involved in tumor cell extravasation and colonization [84-87]. Thus,
down-regulation of MMP-9 by intravenous administration of AM9D was expected to
inhibit the tumor cells from participating in extravasation and seeding of the tumor cells
in the lungs. Consequently, the number of lung colonies will be reduced and further lead
to increased survival of mice compared to control treated counterparts.
Using an experimental lung metastasis animal model, we have shown that both
AM9D and control DNAzyme treatment were equally effective in inhibiting early stage
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experimental metastasis. However, mice treated with these two cohorts did not show
statistically significant overall increased survival.
MATERIALS AND METHODS
Establishing eIF1 alpha-Luciferase2 Mammary Tumor Epithelial Cells
(luc-MTECs)1
Several late stage mammary tumors (>500 mm3) were isolated from Hif1a DF;
PyMT+ females. Tumors were chopped with scalpels then with razor blades and the paste
digested with type III collagenase (1 mg/ml, Worthington Biochemical, Lakewood, NJ)
in RPMI media containing 5% FBS (5 ml/g tissue) for 2 hours at 37°C. Cells were
pelleted at 1100 rpm and then washed 4 times with digestion buffer. Cells were plated
with F12 medium containing 5 g/ml insulin, 2 g/ml hydrocortisone, 5 ng/ml EGF,
50 g/ml gentamycin, 100 U penicillin/streptomycin and 10% FCS, as described by
Rijnkels, M., et al. [88]. After 48-72 h, the plating medium was switched to complete
mammary cell growth medium (DMEM/F12, 5% FBS, 5 mg/ml insulin, 10 ng/ml EGF).
A subset of MTECs was subsequently weaned to reduced growth factor media
(DMEM/F12 + 2% FBS or DMEM/F12 + 0.5% FBS). For sub-cultivation, cells were
rinsed twice with Puck's A saline, then incubated for up to 60 min at 37°C in a 3:1
solution of dispase II/0.025% trypsin reconstituted in Puck's A saline. No EDTA was
utilized for subcultivating cells, as we found that treating cells with trypsin-EDTA
changed tumor cell morphology from an epithelial (cuboidal) to a mesenchymal (spindle)
appearance. The luciferase expressing MTEC cells were generated by transducing
monolayer cultured WT cells with pEILP (eIF1alpha-Luciferase2-IRES-puromycin,
Junming Yue, UTHSC Viral Vector Core) lentivirus particles at 10 m.o.i. For 48 h hours,
followed by washing and immediate selection with puromycin to establish pools of stable
transfectants. All cells were passaged fewer than 30 times and media was routinely tested
for mycoplasma using the MycoAlert kit (Lonza, Basel, Switzerland).
Animals
All animal studies were performed in accordance with the guidelines established
by the Animal Care and Use Committee at The University of Tennessee Health Science
Center. Fifty-six 8-week-old female FVB mice were intravenously injected with
luc-MTECs (1x106 cells) resuspended in 100 l of sterile PBS containing 0.9 mM CaCl2
and 0.493 mM MgCl2. The injected animals were then divided into two groups. Group I
contained 30 mice and group II contained 26 mice.

1

Manuscript in preparation: Schawb, L., Peacock, D., Cushing, R., Majumdar, D., Ingels,
J. and Seagroves, T., Hypoxia Inducible Factor-1a Promotes Primary Tumor Growth and
Tumor-Initiating Cell Activity in the MMTV-PyMT Model of Breast Cancer.
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Group 1. To determine the effect of AM9D treatment on early stage of
metastasis, mice in this group were divided into 3 sub-groups of 10 mice each. On day
1-post MTEC injections the mice received weekly injections of PBS (100 l; subgroup
1a), AM9D (1500 g/100 l PBS; subgroup 1b) or control DNAzyme (1500 g/100 l
PBS; subgroup 1c). All animals were anesthetized with isoflurane before each injection.
Mice received a total of 3 treatments on days 1, 7, and 14 post tumor cells injections and
were euthanized one week after the last DNAzyme treatment (Day 21). Mice were
weighed weekly and observed for any signs of lethargy (i.e. weight loss, trouble
breathing, not grooming) during treatment. Xenogen Bio-imager was used to monitor the
development of lung nodules on days 14 and 21 post tumor cell inoculation. The
luciferase positive cells were identified in lungs on day 21-post tumor inoculation at
which time treatments were stopped and animals were sacrificed. Their lungs were
inflated with 4% paraformaldehyde by cannulation of the trachea, excised, and
photographed for any visual macro metastasis. Lungs were then fixed in 4%
paraformaldehyde overnight. Paraffin embedded, 4 micron frozen sections were prepared
and analyzed by Dr. Stanley Kosanke (Pathologist, University of Oklahoma). The lung
sections were analyzed for the presence of macro and micro lung metastasis. At necropsy,
liver, heart, brain, kidney, and spleen were collected and fixed in 4% paraformaldehyde,
impregnated with 25% sucrose that acts as a cryoprotectant, and were processed for
histopathological evaluation (standard light microscopic examination of hematoxylin and
eosin-stained tissue slides).
Group 2. To determine the effect of AM9D treatment on survival of the animals
with lung nodules, the MTEC inoculated mice were divided into 3 subgroups of 8-9 mice
each. The mice in this group received weekly injections of PBS (100 l; subgroup 2a;
n=8), AM9D (1500 g/100 l PBS; subgroup 2b; n=9) or control DNAzyme (1500
g/100 l PBS; subgroup 2c; n=9) starting from the first day post MTEC injection. Mice
were weighed weekly and monitored for any signs of lethargy (i.e. weight loss, trouble
breathing, not grooming). The animals were then sacrificed when they lost ~20% body
weight, or if they had trouble breathing, were panting and not grooming. The maximum
treatment received by the last surviving animals was 9 injections and these animals were
euthanized one week after the last treatment. Lungs were excised, photographed, weighed
and fixed in 4% paraformaldehyde, as stated above.
RESULTS AND DISCUSSION
Effect of AM9D Treatment on Early Stage Experimental Metastasis
The efficacy of AM9D treatment in inhibiting and/or reducing early stage
experimental metastasis was tested by treating luciferase labeled MTEC (luc-MTEC)
inoculated FVB mice with PBS, 1500 g of either AM9D or control DNAzyme, once a
week for three weeks. The animals were monitored weekly for the presence of luc-MTEC
in lung by Xenogen. At the earliest detection of MTEC in the lung (twenty one days after
the initial treatment), animals were sacrificed. Luc-MTEC injected via tail vein of the
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animals were able to metastasize to and colonize in the lungs (Figure 4-1). The average
number of gross macro metastases observed in AM9D (1.1 ± 1.5) and control DNAzyme
treated animals (1.6 ± 3) were, however lower than that of PBS treated groups
(20.25 ± 31.3; Figure 4-2). This data suggests that AM9D and control DNAzyme
treatment were equally effective in inhibiting metastasis and lung colonization. However,
we cannot ignore the large standard deviation in the PBS control cohort due to the
variability of 0 to more than 70 surface nodules observed at this stage of experimental
metastasis. The analysis of macro metastasis in sectioned lung tissue revealed that AM9D
therapy retarded lung metastasis by 56% compared to PBS, however, control DNAzyme
treatment was 72% and 88% more effective in reducing lung macro metastasis than both
AM9D and PBS treatments, respectively (Figure 4-2b).
The analysis of micro metastasis in sectioned lung tissues also revealed that
control DNAzyme therapy retarded lung micro metastasis by 34% and 24% compared to
AM9D and PBS treatment, respectively (Figure 4-2c). As mentioned above, a few mice
in each group did not show any signs of gross macro metastasis (Figure 4-1a). However,
analysis of lung tissue slices revealed that majority of the animals developed lung
nodules, irrespective of lack of gross lung macro metastasis. The percentages of control
DNAzyme, AM9D, and PBS treated animals that did not show any gross macro
metastasis were 57%, 50%, and 37%, respectively. These data suggest that AM9D and
control DNAzyme therapy are equally affective in reducing lung metastasis. These data
also suggest that although AM9D down-regulates MMP-9 protein production in vitro and
in vivo, both AM9D and control DNAzyme may have a sequence-related off target effect.
Bacterial DNA containing unmethylated CpG dideoxynucleotide sequence motifs
have been shown to stimulate immune cells and this stimulatory effect can be mimicked

Figure 4-1. Representative lungs images extracted from two mice in the PBS
treated group at early stage experimental metastasis.
PBS treated mice had (a) as few as no macromets to (b) greater than 70 macromets as
visualized by gross tissue analysis. Arrows in (b) are pointing to macromets.
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Figure 4-2.
metastasis.

Macro and micro metastasis in lungs from early stage experimental

Luc-MTEC inoculated Mice were treated weekly with PBS or 1500 g of either AM9D
or control DNAzyme for 3 weeks and their lungs were analyzed grossly for (a) macro
metastasis (p=0.092) and a section from each lung were analyzed for (b) macro
metastasis (p=0.146) and (c) micro metastasis (p=0.538).
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by synthetic CpG containing oligodeoxynucleotide (CpG-ODN) [89]. CpG motifs have
been shown in literature to activate Toll-like receptor 9 (TLR9) and lead to the activation
of macrophages, dendritic cells, and B cells [89, 90]. This activation is important for the
treatment of cancer. CpG monotherapy is sufficient for inducing T-cell-mediated
rejection of established tumors [91]. For these reasons, synthetic CpG-ODNs are
currently in human clinical trials for the treatment of cancer [89]. In addition, CpG’s that
contain a purine two bases ahead of or a pyrimidine two bases after the CG nucleotides
have been shown to be more stimulatory compared to CpG-ODNs that do not [90]. The
sequences of AM9D and the control DNAzyme each contain two CpG motifs making
them possible functional CpG-ODNs (Figure 4-3). The presence of macrophages and
dendritic cells in lungs of animals treated with AM9D and control DNAzyme should
attest to this hypothesis. Macrophages and dendritic cells were not observed in lungs 7
days after injection, however, lungs should be observed at a shorter time after injection.
AM9D was well tolerated in this early stage experimental metastasis mouse
model. Body weights of animals in all groups were similar throughout the 3 weeks of
treatment and at sacrifice (Figure 4-4). No obvious adverse effects, including swelling of
joints and difficulty in walking, were observed in DNAzyme-treated mice. Furthermore,
analysis of organs from mice exposed to weekly injections of AM9D or control
DNAzyme for 10 weeks showed no toxic effects (Figure 4-5).
Effect of Long Term AM9D Treatment on Lung Tumor Load in Experimental
Metastasis and on Survival
The efficacy of long term AM9D therapy to reduce lung tumor load and increase
survival was tested by intravenously injecting PBS or 1500 g of AM9D or control
DNAzyme into 8 week old female FVB mice previously injected with 1x106 luc-MTECs,
once a week until mice showed signs of lethargy (~20% weight loss, trouble
breathing/panting, and/or not grooming). The animals were then sacrificed; their lungs
were excised, weighed, and photographed. Mice were observed bi-weekly to determine
changes in health and weighed weekly (Figure 4-6a). The lungs of all animals sacrificed
due illness were completely covered with macro metastasis and no differences between
the wet weight of lungs extracted from AM9D and control treated animals was observed
(Figure 4-6b). Lungs in the PBS treated cohort showed a slightly elevated lung tumor
burden (calculated by dividing lung weight by body weight; Figure 4-6c) compared to
control DNAzyme and AM9D treated mice. Mice in the AM9D treated group displayed
increased signs of progression-free survival between analysis points 34 to 42 days,
however there was no significant extended survival compared to the control treated
groups (log rank test, p>0.05; Figure 4-7). This data is consistent with the results
obtained from Marimastat clinical trial studies demonstrating that progression-free
survival significantly increased in the patients with inoperable gastric cancer using
Marimastat, but overall survival did not improve. In subgroups of patients with prior
chemotherapy and of patients without distant metastases, overall survival was
significantly better in the Marimastat-treated group [45]. These data suggest that AM9D
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Figure 4-3.

CpG regions in AM9D and control DNAzyme.

AM9D and control DNAzyme both contain two CpG regions (red). In each of these
sequences one of the CpG regions has a pyrimidine 2 spaces after (orange). In the AM9D
sequence there is a purine 2 spaces before the CpG region (blue).

Figure 4-4.

Mouse body weights measured during experimental metastasis

The body weights of all the experimental animals were maintained during the course of
the treatment (3 weeks) and no difference in body weights was observed between PBS
(green), AM9D (blue) or control DNAzyme (red) treatment groups.

41

Figure 4-5.

Analysis of mice organ pathology.

Mice intravenously injected with luc-MTEC and treated with once weekly injections of
1500 g of either AM9D or control DNAzyme showed no difference in organ pathology.
Representative images of various organs of AM9D and control DNAzyme treated mice
shown (400x magnification).
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Figure 4-6.

Effect of various treatments on mice lung tumor burden.

(a) Mice treated with once weekly injections of PBS or 1500 g of either AM9D or
control DNAzyme were weighed on their final day of survival. Mice lungs were
weighed upon excision (b) and their total lung tumor burden (c) was calculated. Weights
of mice and lungs and calculation of lung tumor burden did not show a significant
difference between AM9D, control DNAzyme, and PBS treated groups (p>0.05; error
bars show standard deviation).
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Figure 4-7.

Survival curve.

Survival curve of mice injected with 1x106 luc-MTEC and treated with weekly injections
of 100 l PBS (green), 1500 g AM9D (blue) or control DNAzyme (red). Log Rank Test
p=0.5.
can be used as an adjuvant to primary surgery in order to blunt tumor growth and treat
metastasis.
The lack of effect of long term AM9D treatment on tumor growth and overall
survival in this experimental metastasis model may be due to time of AM9D delivery,
frequency of delivery, mouse strain, pro-tumorigenic effects of MMP-9 downregulation,
or a combination of these effects.
Time of delivery and/or frequency of delivery of AM9D may be responsible for
the lack of significant decreased tumor burden in AM9D treated mice compared to
control cohorts. Shibue, et al., have shown that D2 cells extravasate into lungs between
3-48 h after tail vein injection [92]. If MMTV-PyMT MTECs mimic this behavior,
DNAzyme treatment may have been administered too late to block extravasation and
colonization. Chen, et al., showed that treatment of CT26 (colon carcinoma cells)
inoculated mice with 40 mg/kg/day of doxycyclin starting immediately or 2-weeks after
tumor cell injections resulted in fewer but larger and more vascularized lung tumors. On
the other hand, when therapy started at the time of tumor injections, mice had fewer lung
tumors than mice treated 2-weeks after injection of colon carcinoma cells [83]. This
suggests that the time and/or the frequency of the treatment have significant effect on
development of lung experimental metastasis. In both early stage metastasis and long
term AM9D treatment experimental groups, DNAzyme treatment began one day after
injection of MTEC tumor cells and continued once weekly. The data presented in
Chapter 3 (Distribution, Clearance, and Cytotoxicity of DNAzyme) indicated that
DNAzyme administrated intravenously is cleared from the lung within 24 h, but has an
extended clearance from mammary tumors. Therefore, while weekly intratumoral
injections may have been effective in reducing tumor growth (Figure 2-4), it may not be
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sufficient for treatment of lung metastasis. If the observed lack of significant effect of
AM9D therapy on survival of animals with lung metastasis is due to time of initial
treatment or frequency of drug delivery, future experiments with DNAzyme treatment
should begin in advance to or at the same time as tumor cell inoculations and delivered
more frequently. We have observed, however that bi weekly injections (100 l/injection),
via tail vein results in hardening of the tail and necrosis. Therefore, the use of a different
avenue of DNAzyme delivery is a necessity. Jugular vein may be the most efficient route
for delivery of AM9D. This would allow for daily administration of 75 mg/kg AM9D,
which would result in a total delivery of 525 mg DNAzyme/kg/week.
As mentioned above, Chen, et al., showed that intravenous administration of
40 mg/kg/day of doxycyclin into animals inoculated with CT26 (colon carcinoma cells)
immediately or 2-weeks after tumor cell injections resulted in fewer but larger and more
vascularized lung tumors. The increased vascularization was attributed to decreased
production of angiostatin by MMP-9 [83]. Thus, MMP-9 inhibitors may have a null or
pro-tumorigenic effect when administered intravenously. If anti-MMP-9 DNAzyme
(AM9D) therapy leads to (1) decreased MMP-9 protein, (2) decreased anti-angiogenic
factors, and (3) subsequent increased vascularization, then it is expected that AM9D
treated animals develop larger lung tumors and have a decreased survival rate than the
control DNAzyme and PBS treated cohorts. This is contrary to our observation that the
AM9D treated mice showed increased signs of progression-free survival between
analysis points 34 to 42 days compared to control cohorts (Figure 4-7). Hence, while
AM9D did not show extended survival compared to control treated animals, it also did
not show detrimental effects such as larger tumors or decreased survival. Thereby, the
therapeutic effect of AM9D on experimental metastasis should continue to be evaluated
with several adjustments in treatment regimen.
Another possibility for the observed lack of significant outcome of AM9D
therapy on lung experimental metastasis may be related to the mouse strain used in these
studies. Martin et al. showed that the treatment outcome of a gelatinase inhibitor,
SB-3CT, on experimental metastasis is strain dependent [68]. In their experiments,
luciferase-labeled 17L3C cells (MTEC from MMTV-PyMT mice) were injected via tail
vein into C57BL/6 and FVB/N mice followed by daily injections of 50 mg/kg of the drug
SB-3CT or vehicle for 14 days. They found that SB-3CT therapy resulted in a significant
decrease in tumor growth in C57BL/6 mice, while mice on a FVB/N background showed
enhanced tumor growth according to luciferase signal upon treatment. The mice utilized
in our experimental metastasis model are FVB/N, the same strain that showed enhanced
tumor growth when treated with a gelatinase inhibitor in the Martin, et al. publication
[68]. These data suggest that the mice with different genetic backgrounds should be used
to assess the significance of genetics on efficacy of AM9D in experimental metastasis.
In Chapter 2, I have shown that AM9D is able to reduce tumor growth by up to
50%. In order to determine if AM9D can be used in the treatment of breast cancer
metastasis, the determining factor in breast cancer patient survival, the aforementioned
experiments (including changes in time and frequency of treatment) must be performed.

45

CHAPTER 5.

MMP-9 TRESSPASSES ON MMP-1’S TURF
INTRODUCTION

High expression levels of a variety of Matrix Metalloproteinases (MMPs),
including MMP-1 and MMP-9 have been reported to be associated with progression and
poor prognosis of breast cancer [93-95]. MMP-1 and -9 degrade type I and type IV
collagen, respectively, two of the most abundant collagens in the ECM [11], making both
enzymes important in cancer development, proliferation, and angiogenesis through their
involvement in ECM degradation and cytokine release and activation [10, 11]. With the
use of a transgenic multistage carcinogenic mouse model, MMP-9 has been shown to be
up regulated in angiogenic islets, leading to an increase in the bioavailability of VEGF
[30]. MMP-1 has been shown to be one of the most highly over expressed genes in bone
metastasis [7]. In addition, researchers have shown that the presence of MMP-1 in the
stromal-tumor microenvironment plays a role in altering the behavior of tumor cells by
binding to and activating PAR1 and facilitating invasion [5, 96]. We have shown that
down regulation of MMP-9 by AM9D inhibits the invasion of MDA-MB-231 cells
(Chapter 1, Figure 1-3d). Thus, inhibition of MMP-1 and -9 expression can be used as a
therapeutic modality to decrease growth and invasion of tumor cells.
Although MMP-1 and -9 have different substrate specificity, they are both
composed of three major domains: NH2-terminal pro-domain, central catalytic domain,
and COOH-terminal hemopexin-like domain connected to catalytic domain via a
proline-rich hinge region (Figures 1-1 and 5-1). The hinge region of MMP-9 is extended
and is similar to Type V collagen. During protein activation, the pro-domain is cleaved
[97]. MMP-9 has an additional domain known as the gelatin binding domain composed
of 3 homology fibronectin-type II modules of 58 amino acids inserted into the catalytic
domain (Figure 5-1b) [98]. We have shown that this domain is responsible for the type V
collagen activity of the enzyme [40, 99]. The carboxyl-terminal domain of MMP-9 is
involved in anchoring the enzyme to CD44 [100-102] and binds to heparin [103].
Although, the role and significance of individual domains in substrate recognition by
MMP-9 has been defined, the enzyme reaction mechanism of MMP-9 has yet to be
determined.
Latent MMP-9 is a 92 kDa protein that upon activation is converted to an 82 kDa
protein that auto-catalytically process to a 68 kDa (fully processed) species [104]. Many
cell lines studied contain both 82 kDa and 68 kDa proteins [102, 104]. In an attempt to
delineate the complete role of MMP-9 in breast cancer, we isolated and purified the 92
kDa latent MMP-9 from a highly invasive human breast cancer cell line, MDA-MB-231
and demonstrated that it can be fully processed to a 68 kDa protein upon activation. The
amino terminal amino acid analysis of the 68 kDa protein revealed that it has the same
NH3-termini, Met75, as the 82 kDa protein, indicating that 68 kDa protein is a carboxyl
terminal truncated form of the enzyme. Further characterization of the 68 kDa protein
revealed that the enzyme in addition to gelatin and types V and XI collagens, similar to
MMP-1, was also able to cleave native triple helical type I collagen. As mentioned
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Figure 5-1.

Schematic diagram of MMP-1 and -9.

The enzymes share pro-domain (grey), a catalytic domain (yellow and red), a hinge
region domain (black jagged line), and a c-terminal hemopexin-like domain (dark blue).
The catalytic domain of all MMPs contain a Zn binding active site (AS) region (red). The
hinge region domain is located between the catalytic and c-terminal hemopexin-like
domain (a and b). MMP-9 contains an extended hinge region, which is often referred to
as the type V collagen-like domain (blue oval) due to its Proline rich composition. The
catalytic domain of MMP-9 contains 3 homology fibronectin-like repeats, shown in light
green (b).
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previously, the 82 kDa protein does not cleave type I collagen as a substrate. These data
suggest that MMP-9 plays a dual role in tumor cell invasion; by cleaving type IV
collagen, it exposes an HUIV26 cryptic site that is important for angiogenesis and tumor
growth [31] and by cleaving type I collagen, the most abundant collagen of the ECM it
aids MMP-1 in increasing the proliferation and invasive potential of tumor cells. This
dual role that MMP-9 plays in tumorigenesis makes it an even more attractive anti-cancer
target. To derive a therapeutic efficient inhibitor specific for MMP-9, it is important to
investigate MMP-9 mechanism of substrate specificity.
In this Chapter, the mechanism of type I collagenolysis of 68 kDa MMP-9 was
investigated by deletion and alanine scanning site directed mutagenesis techniques.
These studies revealed that presence or the lack of interaction between the side chains of
Glu415 in the active site and Glu447 and/or Arg451 located in the hinge region determines
specificity of MMP-9 toward type I collagen substrate. The carboxyl-terminal truncated
68 kDa species lacks both Glu447 and Arg451 thus, its active site is flexible and capable of
accommodating and consequently cleaving type I collagen. On the other hand, the
interaction between Glu415 and Glu447 and/or Arg451 makes the active site of 82 kDa
MMP-9 rigid, preventing the enzyme from cleaving type I collagen as a substrate.
MATERIALS AND METHODS
Mutagenesis
MMP-9 444-502. Type-V like hinge domain (amino acid residues 444-502) was
deleted from the full-length MMP-9 cDNA (pETNG) by the polymerase chain reaction
(PCR) procedure. The pETNG expression system containing full length MMP-9 cDNA
[75] was used as a template for two separate PCR reactions. The 5’ primer, 5’-AAG
GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ and 3’ primer,
5’-GG CAC AGT AGT GGC ACC ATA GAG GTG CCG GAT GCC-3’ were used to
amplify a 1.55kb region of the pETNG corresponding to nucleotides 43 to 1593 and the
5’ primer , 5’-GGC ATC CGG CAC CTC TAT GGT / GCC ACT ACT GTG CC-3’ and
3’ primer , 5’-TCG AGG TCG ACG GTA TCG ATA AGC TTG ATA TCG AAT-3’
were used to generate a ~0.85 kb PCR product corresponding to nucleotides 1381 to
2400 (1401-1575 looped out) of the MMP-9 sequence. The PCR products were
sequenced to verify that the desired deletion mutation is the only mutation generated by
PCR. The 1.55 kb and 0.85 kb PCR products were used to generate 2.3 kb MMP-9
cDNA lacking Type-V like hinge domain (nucleotides 1401-1575) by PCR using
5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ and,
5’-TCG AGG TCG ACG GTA TCG ATA AGC TTG ATA TCG AAT-3’ as 5’ and 3’
primers, respectively. The 2.3 kb PCR product was digested with restriction enzymes
XbaI and SalI and the 2.2 kb XbaI/SalI cDNA fragment was ligated to NheI/SalI
fragment of the expression vector pET12C for 1 h at room temperature using T4 DNA
Ligase (Promega, Madison, WI) to generate pET444-502.
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Alanine Scanning Site-Directed Mutations in CT(1-456). The following 3’
mutagenic primers were used to substitute Arg445 (nucleotides 1405-07), Glu447
(nucleotides 1411-13), Glu449 (nucleotides 1417-19) or Arg451 (nucleotides 1423-25) with
Ala (substituted nucleotide(s) underlined) and generate a stop codon at position 446
(nucleotide 1439) in MMP-9 molecule using pETNG as template: R445A, 5’-GAC TCT
AGA CTA TTA GGT GGT GGT TGG AGG CCG TGG CTC AGG TTC AGG GGC
AGG ACC ATA-3’; E447A, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT
TGG AGG CCG TGG CTC AGG TGC AGG GCG AGG-3’; E449A, 5’-CAG GTC
GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG CCG TGG CGC AGG TTC
AGG-3’; R451A, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG
CGC TGG CTC AGG-3’. All of the above primers were complimentary to nucleotides
1401-1439 in NG and contained a unique XbaI restriction site (TCT AGA) and a STOP
codon (TAG) at the 3’end. The 5’ primer used in all of the above PCR reactions was
5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’. All the
PCR products were sequenced by Dideoxy method [99] and were found to be free of any
secondary mutations. The resulting PCR products were digested with XbaI and SalI and
ligated to NheI /SalI fragment of pET-12C expression vector.
E415G in CT(1-456). This mutant was generated using two PCR reactions and
pETNG as a template. The first PCR used 5’ primer, 5’-CAT TCC TCA GTG CCG GGG
GCG CTC ATG TAC CC-3’ and 3’ primer, 5’-CAG GTC GAC TCT AGA CTA TTA
GGT GGT GGT TGG AGG-3’ to generate a 160 bp PCR fragment containing
nucleotides 1300 to 1440. The above 5’ primer contained a unique XbaI restriction site
(TCT AGA) and a STOP codon (TAG) at the 3’end. This 160bp fragment was used as a
3’primer for the second round of PCR using pETNG as a template and 5’-AAG GAG
ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ as 5’ primer. This
generated a 1.4 kb PCR product (nucleotides 43-1440), which was digested with
restriction enzymes NdeI and XbaI and ligated to NdeI-NheI fragment of pET-12c
expression vector as described above.
Double Mutant. The CT(1-456) E415G/E447A mutant was generated using the
previously published Gel. B/E415G mutant in pET-12c as a template [105]. The 5’
primer, 5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’
and 3’ primer, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG
CCG TGG CTC AGG TGC AGG GCG AGG-3’, were used to generate Glu to Ala
mutation at position 447 (nucleotides 1341-1343) and a stop codon at position 456
(nucleotide 1439) in MMP-9 E415G mutant protein resulting in CT(1-456) truncated
mutant with Glu415 to Gly and Glu447 to Ala substitutions. The PCR product was digested
with XbaI and SalI and ligated with NheI and SalI fragment of pET-12c expression
vector (Novagen, Rockland, MA).
Enzyme Purification. Plasmids encoding for wild-type and mutant enzymes were
introduced into E. coli strain BL21(DE3)(pLysS), the cells bearing the plasmids were
induced by IPTG and the latent recombinant proteins were purified on gelatin-agarose
affinity columns as described previously [75]. Purified enzymes were dialyzed against
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50mM Tris-HCl, pH 7.5, 5mM CaCl2, 150mM NaCl, and 2mM ZnCl2 and stored at
-20 ˚C until use.
Gelatin Zymography
The activity of the purified enzymes toward gelatin was assessed by running
proteins on a non-reducing SDS/Polyacrylamide gel (8%) containing 1 mg/ml gelatin.
Protein samples were mixed with the SDS/PAGE sample buffer without reducing agents
and were loaded without being boiled. After electrophoresis, the gels were washed twice
with 50 mM Tris-HCl, 5 mM CaCl2, 1 mM ZnCl2, 1% Triton X-100, and 0.02% NaN3
at 25 ˚C and incubated in the same buffer for 16 h at 37 ˚C. The gels were stained with
Coomassie Brilliant Blue. Gelatin zymography depicts MMPs as negatively stained
bands of gelatinolytic activity.
Determination of Kcat/Km Values for the Fluorogenic Peptide Substrate
Mca-PLGL(Dpa)AR-NH2.
The latent enzymes were activated by 1 mM APMA at 37ºC for 14-16 h. The
concentrations of the active enzymes, [E]T, were determined by active-site titration with
the MMP inhibitor GM6001 as described previously [106]. The Kcat/Km values for the
fluorogenic peptide substrate were then obtained by assaying the enzymes at 23ºC using
1.5 M peptide substrate as previously described [99]. Assays were conducted under the
condition where Km >> [S], and Kcat /Km values were calculated from the following
equation: Kcat /Km = vo / [E]T[S].
Kinetic Analysis of Type I Collagenolytic Activity
To determine the Kcat/Km values of the MMP-9 mutant enzymes for type I
collagen, enzymes (0.02 M) were mixed with various concentrations of bovine type I
collagen (1.1, 1.65, 2.2, and 2.75 μM) in assay buffer that was composed of 50 mM Tris,
pH 7.5, 5 mM CaCl2, 150 mM NaCl, and 2 μM ZnCl2. Reactions were allowed to
proceed at 27 °C for 6 h before being quenched by the presence of 10 mM EDTA.
Reaction mixtures were boiled for 5 min and electrophoresed on 8% SDS-PAGE.
Proteins bands were visualized by Coomassie Brilliant Blue staining. The integrated
intensities of the 1(I) and 2(I) collagen bands were determined by using an Alpha
Imager 2000 documentation and analysis system (Alpha Innotech Corp., San Leandro,
CA). The difference between the integrated intensities of the 1(I) collagen band in the
presence and in the absence of the enzyme was used to calculate the catalytic activity of
the enzyme as described previously [107].
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Analysis of Gelatinolytic Activity of the Enzymes
The gelatinolytic activity of enzymes was determined using 14C-labeled gelatin as
described previously [40, 108, 109]. Specific activity was calculated by dividing the
amount of gelatin degraded per hour by the nanomoles of enzyme present in the assay.
The assays were performed in triplicates and the results were averaged.
RESULTS
Expression, Purification, and Activation of Deletion Mutant Enzymes
The major aim of this study was to identify the structural elements that are
sufficient to endow MMP-9 with type I collagenolytic activity. Since the fully processed
carboxyl-terminal truncated MMP-9 (68 kDa protein) was shown to be able to cleave
type I collagen, a series of MMP-9 deletion mutant enzymes (Figure 5-2) were designed
to address the role and significance of the hemopexin domain and hinge region in type I
collagen substrate specificity of MMP-9. The first deletion mutant, CT(1-456) consisted of
complete deletion of the hemopexin domain (amino acid 503-706) and partial deletion of
the hinge region (amino acid 457-502). CT(1-443) consisted of complete deletion of both
the hemopexin domain and the hinge region (amino acids 444-706). The 444-502
mutant is comprised of MMP-9 molecule lacking only the hinge region, amino acid
residues 444-502. All mutant enzymes were expressed in E. coli as latent enzymes and
purified on gelatin agarose affinity column as described previously [75].
Characterization of Deletion Mutants MMP-9
To assess whether deletion mutants were correctly folded and retained general
proteolytic activity, they were activated with APMA and the catalytic efficiencies of
MMP-9, CT(1-456), CT(1-443) and MMP-9 444-502 enzymes toward gelatin and a
general MMP fluorogenic peptide substrate, Mca-PLGL(Dpa)AR-NH2, were determined.
As demonstrated in Figure 5-3 and Table 5-1, all activated mutant enzymes were able to
cleave gelatin. However, only the 444-502 mutant enzyme with intact hemopexin
domain had similar gelatinolytic activity as the wild type MMP-9. All other deletion
mutations resulted in a decreased catalytic efficiency of the enzyme toward
gelatin substrate. CT(1-456) and CT(1-443) mutants had 3.2-fold and 3.6-fold lower
activity toward gelatin compared to WT MMP-9, respectively (Table 5-1). This is
consistent with Roeb, et al., finding that MMP-9 hemopexin domain has a high affinity
for gelatin [103]. Therefore it is not surprising that CT(1-443) and CT(1-456), both lacking
the hemopexin domain, had lower activity toward gelatin substrate while, specific
activity of MMP-9 hinge region deleted mutant (444-502) for gelatin was similar to that
of the wild type enzyme.
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Figure 5-2.

MMP-9 recombinant deletion mutants.

Full-length MMP-9 is comprised of 706 amino acids and does not use type I collagen as a
substrate. 444-502 mutant is comprised of MMP-9 molecule lacking hinge region,
amino acid residues 444-502. CT(1-456) recombinant mutant lacks amino acid residues
457-706 corresponding to the hemopexin domain and partial hinge region. In CT(1-443)
recombinant mutant both hemopexin domain and hinge region were deleted (amino acid
residues 444-706).

52

Figure 5-3.

Gelatin- gel zymography of purified mutant enzymes.

(a) Lanes 1, 3, and 5 show the latent form of WT MMP-9, CT(1-456) and CT(1-443),
respectively. Lanes 2, 4, and 6 shows the active form of WT MMP-9, CT(1-456) and
CT(1-443), respectively. (b) Lanes 1 and 2 show the latent and active forms of 444-502,
respectively.
Table 5-1.
Enzyme
M-1

Proteolytic activity of deletion mutant enzymes

MMP-1

Kcat/Km
Specific Activity Kcat
(McaPLGLDpaAR) for Gelatin
Type I
mM-1S-1
g/h/nmol
collagen
h-1
14.17 ± 0.5
272 ± 9
146

Km
Type I
collagen
M-1
5.36

Kcat/Km
Type I
collagen
h-1 M-1
27.23

MMP-9

585 ± 30.9

187,669± 11,921 ND

ND

ND

444-502

145.33 ± 2.58

187,157 ± 224

33.03

8.9

3.71

CT(1-456)

128.9 ± 14.1

58,959 ± 359

ND

ND

ND

CT(1-443)

613 ± 2.1

52,272 ± 5149

3.7

2.1

1.8

ND=Not Determined
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As shown in Table 5-1, the catalytic efficiency (Kcat/Km) of both CT(1-456) and
444-502 toward the Mca-PLGL(Dpa)AR-NH2 were 4.5 and 4 times lower than that of
the wild type enzyme, respectively. The CT(1-443) mutant, however, had similar Kcat/Km
for the peptide substrate to wild type MMP-9 (585 ± 30.9 mM-1 S-1). These findings
suggest that presence of amino acid residues 444-456 in the hinge region plays a role in
general proteolytic activity of the enzyme.
As mentioned previously, contrary to 82 kDa MMP-9, the 68 kDa active MMP-9
cleaves type I collagen, suggesting a role for carboxyl terminal domain and hinge region
in type I collagenolytic activity of the enzyme. Therefore, the ability of deletion mutants
to cleave type I collagen was assessed. As demonstrated in Table 5-1, only deletion
mutants lacking the entire hinge region with (444-502) or without (CT(1-443)) the
carboxyl terminal domain were able to cleave type I collagen. CT(1-443), in addition to
gelatin and type V collagen (data not shown), was able to use triple helical type I
collagen as a substrate (Table 5-1) with Kcat/Km value of 1.8 h-1 M-1. This value is 15.1
times lower than the value obtained for MMP-1 (27.23 h-1 M-1). Interestingly, contrary
to this enzyme, CT(1-456) does not cleave type I collagen, suggesting that presence of
amino acids 444-456 in the CT(1-456) molecule hinders the enzyme from utilizing type I
collagen as a substrate. This hypothesis was confirmed by the observation that complete
deletion of the hinge region from the full length MMP-9 (444-502) endowed the
enzyme with type I collagenolytic activity. The catalytic efficiency of the 444-502
mutant toward type I collagen substrate was 3.71 h-1 M-1 (Table 5-1). This values is 2
times higher than the value obtained for CT(1-443). This may be due to the hemopexin
domain binding to and helping to present type I collagen to the AS in 444-502
molecule.
Glu447 and Arg451 Residues in the Hinge Region Play a Role in Type I Collagenolytic
Activity of MMP-9
Analysis of activity of CT(1-456) and CT(1-443) enzymes toward type I collagen
substrate suggested that the 13 amino acid residues, 444PRPEPEPRPPTTT456 in the hinge
region of MMP-9 determines the substrate specificity of the enzyme (Figure 5-4,
Table 5-2). The role of specific amino acid residues in this region of the MMP-9
molecule in its type I collagenolytic activity was evaluated by alanine scanning site
directed mutagenesis. The charged amino acid residues, Arg445, Glu447, Glu449 and Arg451
in CT(1-456) (Figure 5-4) were individually substituted with Ala and the effect of each
mutation on substrate specificity of the enzyme was evaluated. All site directed mutant
enzymes were expressed in E. coli, purified, and their enzymatic activities were
determined following activation by APMA.
Gelatin gel zymography showed that upon activation with APMA, the 45 kDa
unglycosylated latent R445A, E447A, E449A, and R451A CT(1-456) mutant enzymes
were converted to 37 kDa active species (Figure 5-5) as expected.
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Figure 5-4.

Alanine mutations in CT(1-456).

Schematic diagram of CT(1-456), showing the amino acid residues in the hinge region
involved in type I collagenolytic activity of the enzyme. The amino acids in red signify
the amino acids individually mutated to Ala.
Table 5-2.
Enzyme
M-1

Proteolytic activity of the Ala mutants

MMP-1

Kcat/Km
Specific Activity Kcat
(McaPLGLDpaAR) for Gelatin
Type I
mM-1S-1
g/h/nmol
collagen
h-1
14.17 ± 0.5
272 ± 9
146

Km
Type I
collagen
M-1
5.36

Kcat/Km
Type I
collagen
h-1 M-1
27.23

CT(1-456)

128.9 ± 14.1

58,959 ± 359

ND

ND

ND

R445A

328.1 ± 11.9

71,154 ± 174

ND

ND

ND

E447A

85.95 ± 1.5

10,239 ± 130

0.418

0.157

2.66

E449A

275.37 ± 16.8

149,680± 19,758 ND

ND

ND

R451A

135.1 ± 10.26

248,706± 13,896 0.641

0.236

2.71

ND=Not Determined
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Figure 5-5.

Gelatin- gel zymography of purified site directed mutant enzymes.

Lanes 1, 3, 5 and 7 correspond to the latent forms and lanes 2, 4, 6 and 8 correspond to
the active forms of CT(1-456) mutant enzymes R445A, E447A, E449A, and R451A ,
respectively.
The catalytic efficiencies of all of the mutant enzymes toward the peptide
substrate Mca-PLGL(Dpa)AR-NH2 and gelatin were then determined at 23 ˚C and 37 ˚C,
respectively. As shown in Table 5-2, all of the Ala substitutions changed catalytic
efficiency and specific activity of the CT(1-456) enzyme for peptide substrate and
gelatin, respectively. While, R451A substitution did not have a significant effect on
Kcat/Km value of the CT(1-456 ) for the synthetic substrate , the catalytic efficiency of
R445A and E449A for the substrate were found to be 2.6 and 2.3 times higher than that
of CT(1-456), respectively. The observed differences between catalytic efficiency of
CT(1-456) and the Ala mutant enzymes for synthetic substrate could be due to higher
catalytic activity (Kcat) and/or higher affinity of the mutant enzymes for the synthetic
substrate. The E447A mutant had 1.5 times lower Kcat/Km value for the synthetic
substrate than CT(1-456).
All of the alanine mutations also changed specific activity of CT(1-456) enzyme
for gelatin substrate. While the specific activities of R445A, E449A, and R451A mutants
for gelatin substrate were 1.2, 2.5, and 4.2-fold higher than that of CT(1-456),
respectively, introduction of Ala mutation at position 447 in CT(1-456 ) reduced
gelatinolytic activity of the enzyme by 5.7-fold (Table 5-2). These data suggest that
amino acid residues at positions 447, 449, and 451 are involved in general proteolytic
activity of MMP-9.
The effect of Ala mutations in type I collagenolytic activity of CT(1-456) was
assessed using soluble type I collagen as a substrate. As shown in Table 5-2, substitution
of Glu447 and Arg451 with Ala endowed CT(1-456) with type I collagenolytic activity.
E447A and R451A (Table 5-2) were able to cleave type I collagen less efficiently than
444-502 mutant enzyme (3.71 h-1M-1; Table 5-1). The Kcat/Km of E447A and R451A
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mutants were 2.66 and 2.71 h-1 M-1, respectively (Table 5-2). These data indicate that
the presence of Glu447 and Arg451 residues in MMP-9 hinders the enzymes from cleaving
type I collagen. We have previously shown that presence of Glu415 in the active site of
MMP-9 also prevents the enzyme from using type I collagen as a substrate
[105]. This was based on the observation that substituting Glu415 in the active site of
MMP-9 with Gly, an amino acid counter part in MMP-1, provided the enzyme with type
I collagenolytic activity [105]. These data together suggests that interaction between the
side chain of Glu447 and/or Arg451 with Glu415 make the active site of MMP-9 rigid and
capable of accommodating specific substrates, i.e. gelatin and type V collagen. Removal
of the side chain of either of these amino acid residues or a complete deletion of the hinge
region as in 444-502 and CT(1-443) mutant enzymes makes the structure of the active
site more flexible and capable of cleaving both types I and V collagen.
Interaction Between Glu415 and Glu447 and/or Arg451 Dictates Substrate Specificity
of MMP-9
To test the above hypothesis we introduced Glu415 to Gly mutation into CT(1-456)
and E447A/CT(1-456) enzymes (Figure 5-6) and studied the effect of mutations on type I
collagenolytic activity of the enzymes. If interaction between the side chains of Glu415
and Glu447 dictates substrate specificity of MMP-9, then removal of the side chain
of either amino acids from CT(1-456) should result in an enzyme capable of cleaving type
I collagen in addition to gelatin and synthetic substrate. Moreover, introduction of E415G
mutation in E447A/CT(1-456) should, in principal, increase the activity of the enzyme
toward type I collagen.
As shown in Figure 5-6 and Table 5-3, the latent E415G/CT(1-456) (E415G) and
E415G/E447A/CT(1-456) (DM) are 47 kDa proteins that after activation by APMA are

Figure 5-6.

Schematic diagram and gelatinolytic activities of E415G and DM.

The figure to the left is schematic diagrams of CT(1-456) showing the position of Glu415
and Glu447 in the protein molecule. To the right is a gelatin gel zymography depicting
molecular weights of latent (lanes 1 and 3) and active (lanes 2 and 4) forms of
E415G/CT(1-456) and E415G/E447A/CT(1-456) (DM) mutant enzymes, respectively.
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Table 5-3.
Enzyme
M-1

E415G and DM proteolytic activity.

MMP-1

Specific
Kcat/Km
(McaPLGLDpaAR) Activity for
mM-1S-1
Gelatin
g/h/nmol
14.17 ± 0.5
272 ± 9

Kcat
Type I
collagen
h-1
146

Km
Type I
collagen
M-1
5.36

Kcat/Km
Type I
collagen
h-1 M-1
27.23

CT(1-456)

128.9 ± 14.1

58,959 ± 359

ND

ND

ND

E415G

130.63 ± 0.53

56,779 ± 2,956 8.041

2.3

3.5

DM

29.52 ± 0.6

39,864± 984

1.94

6.1

11.89

ND=Not Determined
converted to 37 kDa proteins capable of cleaving gelatin and using
Mca-PLGL(Dpa)AR-NH2 as a substrate. The catalytic efficiency and specific activity of
E415G for the synthetic substrate and gelatin were equal to those of CT(1-456),
respectively (Table 5-3). Contrary to E415G, the catalytic efficiency of DM mutant
enzyme for the synthetic substrate and its specific activity for gelatin were 4.4 and
1.4-fold lower than those of CT(1-456) (Table 5-3). This data confirms the previous
observation that amino acid residue at position 447 is involved in general proteolytic
activity of MMP-9.
The catalytic efficiency (Kcat/Km) of E415G and DM enzymes for type I
collagen was determined at 27ºC (Table 5-3). We found that similar to previously
described Gel.B/E415G mutant [105], mutation of Glu415 to Gly in CT(1-456) confers the
enzyme with type I collagenolytic activity at an efficiency of 3.5 h-1 M-1 (Table 5-3).
The double mutant had a catalytic efficiency of 6.1 h-1 M-1, which is 1.7- and 2.3-fold
higher compared to individual E415G and E447A mutants, respectively (Table 5-2) and
is equal to the efficiency of single mutants combined. This additive effect of double
mutations on the rate of cleavage of type I collagen by CT(1-456) proves our hypothesis
that the interaction between Glu415 and Glu447 is the major determinant in collagen
substrate specificity. The interaction(s) between the side chains of Glu447 and Glu415
makes the active site rigid, preventing the active site from accommodating type I collagen
molecule. Breaking this interaction by either replacing, Glu447 or Arg451 to Ala makes the
active site flexible and capable of cleaving type I collagen.
DISCUSSION
In this report we demonstrate, for the first time, that the ability of 68 kDa MMP-9
to cleave type I collagen comes from its active site ability to adopt a conformation that
mediates collagen binding and catalysis and this process is dependent on the lack of
interaction between a Glu residue at position 415 located in the AS region of the enzyme
and Glu477 residue located in the hinge region. The removal of amino acid side chain at
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positions 415 and/or 447 provides flexibility necessary for the enzyme active site to
change conformation upon binding collagen, leading to catalysis. This is based on the
observation that only MMP-9 mutants lacking Glu415 (as in E415G), Glu447 (as in E447A,
CT(1-443), and 444-502 mutants), or their combination (as in E447A/E415G/CT(1-456))
were able to use type I collagen as a substrate. The carboxyl terminal deletion mutant
(CT(1-456)) and full length MMP-9 although had high activity toward the peptide
substrate and gelatin, were not able to cleave type I collagen. CT(1-456) was by all
indications stable, properly folded, and able to be processed by APMA to a 37 kDa active
species. An amino acid sequence alignment revealed that the amino acid residues
444-456 (444PRPEPEPRPPTTT456) is responsible for the observed difference in the type I
collagenolytic activity of CT(1-456) and CT(1-443) mutant enzymes (Figure 5-2 and 5-4).
We have previously demonstrated that MMP-9 mutant (Gel.B/E415G), in which
Glu415 located in its active site is substituted by Gly, its corresponding residue in all type
I collagen cleaving MMPs, is able to cleave native triple helical type I collagen [105].
These data together suggested that the interaction between Glu415 and an amino acid
residue(s) in the sequence 444PRPEPEPRPPTTT456 make the active site of MMP-9 rigid,
preventing the enzyme from binding to and cleaving type I collagen.
This was confirmed by the observation that the replacement of Glu447 and Arg451
in CT(1-456) with Ala (E447A and R451A) endowed the enzyme with type I
collagenolytic activity (Table 5-2). These mutants retained peptide substrate and
gelatinolytic activity, indicating that the general proteolytic activity of CT(1-456) was not
compromised by these substitutions. The effect of E447A and R451A mutation on kinetic
parameters of CT(1-456) for type I collagen was similar to the replacement of Glu415 with
Gly in CT(1-456) (Table 5-3) and removal of the entire hinge region of MMP-9
(444-502; Table 5-1). As shown in the diagram below (Figure 5-7), presence of the 13
amino acids in full-length MMP-9 and CT(1-456) makes the AS of these enzymes rigid
and blocks type I collagen from entering the AS. Further processing of 82 kDa by
COOH-terminal truncation, to 68 kDa enzyme and deletion of the remaining hinge region
in CT(1-443) removed the Glu415 and Glu447 interaction and made the AS less rigid. This
allowed type I collagen to enter the AS of CT(1-443) and be cleaved with a Kcat/Km of
1.8 h-1 M-1 (Figure 5-7; bottom left). Substitution of Glu415 with Gly (Figure 5-7; top
right), Glu447 (Figure 5-7; bottom right) or Arg451 with Ala also affected the interaction of
the hinge region with AS Glu415 by breaking the side chain ionic interactions. This made
the active site less rigid and capable of cleaving type I collagen with a Kcat/Km of 3.5,
2.66 and 2.71 h-1 M-1, respectively. These data indicated that the interaction of Glu415
and Glu477 in MMP-9 dictates substrate specificity of the enzyme.
This was substantiated by substituting the Glu415 residue with Gly and Glu477 with
Ala in CT(1-456). The catalytic activity (Kcat) of the double mutant
E415G/E477A/CT(1-456) toward type I collagen was 1.5 and 28.4 folds higher than that
of E415G and E477A mutants, respectively (Table 5-2 and 5-3). The affinity of the
double mutant for type I collagen (Km), however, was similar to that for E415G mutant.
Generation of the E415G/E447A/CT(1-456) (DM) lead to an additive effect on type I
collagen catalytic efficiency. The Kcat/Km of 6.1 h-1 M-1 was approximately 2 times
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Figure 5-7.
activity.

Schematic diagram of MMP-9 mutants with type I collagenolytic

This diagram shows full length MMP-9 without any mutations (upper left) and the
rigidity of the AS caused by the interaction between Glu415 and Glu447, which inhibits
type I collagen (green ball) from entering the AS. When Glu415 is mutated to Gly (upper
right), the hinge region is completely deleted (lower left), or Glu447 is mutated to Ala
(lower right) the interaction between Glu415 and Glu447 is broken and the enzyme gains
type I activity.
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higher compared to E415G, E447A, and R451A single mutations in CT(1-456).
According to the X-ray crystal structures of MMP-9 catalytic domain [105] and
full length MMP-1 [110], Glu415 is located in a turn at the bottom of the AS where the
polypeptide chain turns back towards the center of the enzyme and Glu447 and Arg451 are
located at the beginning of the hinge region (Figure 5-7). Considering that Glu415 is not
positioned along the enzyme/substrate interface, it is unlikely that it or a substituting
residue would directly interact with the collagen substrate. The significance of this
residue in type I collagenolysis is probably related to its direct/indirect interaction with
Glu447/Arg451 affecting the conformation and flexibility of the AS of the enzyme. Thus, it
is conceivable that any substitution at these positions have a general effect on the
mobility of the AS. The observation that the CT(1-443), E415G, E477A R451A and
444-502 mutant enzymes are capable of cleaving type I collagen supports this notion
and suggests that the flexibility provided by the lack of Glu415-Glu447 interaction is
essential for type I collagenolytic activity. Consistent with this hypothesis is also the fact
that full length MMP-9 and CT(1-456) mutant enzymes cannot cleave native type I
collagen substrate (Table 5-1). Thus, it is reasonable to conclude that the interaction of
Glu415 with the hinge region makes the active site rigid, preventing MMP-9 from cleaving
type I collagen. Disruption of this interaction, on the other hand, provides the flexibility
necessary for enzyme active site to change conformation and be able to bind and cleave
collagen substrate.
These data indicate that therapeutic studies which target only MMP-1 may not be
very effective due to the cleavage of type I collagen by the fully processed MMP-9. Thus,
this novel role identified for the type V collagen-like hinge region of MMP-9 in cleavage
of type I collagen aids in understanding the relationship between the structure and
function of MMPs and the involvement of different exocites in the substrate specificity.
This can lead to discovery of novel and targeted therapeutic agents.
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CHAPTER 6.

SUMMARY

Increasing evidence suggests that MMPs contribute to the formation of a
microenvironment that promotes tumor growth during early stages of tumorigenesis.
MMP-9 is one of the most important factors for metastatic behavior of tumor cells [23,
54, 74]. MMP-9 expression has been shown to be upregulated in breast tumors isolated
from cancer patients [73]. MMP-9 degrades type IV collagen, one of the most abundant
collagens in the ECM [11, 75] and is involved in cell proliferation, angiogenesis, and
apoptosis [9, 10, 30]. Our observation that AM9D specifically decreased MMP-9 mRNA
and protein production (Figure 1-3b and c) and reduced invasive behavior of human
MDA-MB-231 cells (Figure 1-3d) suggested that AM9D has potential as an anti
tumorigenic/metastatic agent.
MMTV-PyMT transgenic mice were used to test the effect of AM9D on tumor
growth in vivo. This model was chosen because of its similarity to human breast cancer
and its metastatic potential. AM9D treatment of 10 g and 25 g/tumor/week for a total
of four weeks showed a 39.5 and 50% reduction in final tumor load.
Immunohistochemical analysis of tumor tissues showed that AM9D treatment reduced
MMP-9 production in tumor cells by 66% compared to control DNAzyme treatment. In
addition, AM9D treatment decreased vasculature and induced apoptosis in mammary
tumors as demonstrated by CD31 and Caspase-3 immunostaining, respectively. These
results showed promise as to the use of AM9D to treat tumor growth in vivo. However,
there were several limitations in this study. First, the tumors of the MMTV-PyMT model
developed at different time points and only the earlier developed tumors being treated
with AM9D or control DNAzyme. This led to termination of treatment after 4 injections.
Second, due to the development of the large size mammary tumors during the course of
the treatment, the mice were sacrificed prematurely, inhibiting our ability to fully assess
the effect of AM9D on spontaneous lung metastasis. Thus, experimental metastasis was
utilized to determine the effect of AM9D on metastasis.
To utilize AM9D as a therapeutic treatment in experimental metastasis, AM9D
needed to first be evaluated for its distribution, clearance and safety in normal and
MMTV-PyMT mice. Healthy FVB and MMTV-PyMT mice were injected with naked
[35S]-AM9D (10 mg/kg) in PBS via tail vein. [35S]-DNAzyme was distributed to all
major organs in mice, including liver, kidney, lung, spleen, heart, pancreas, intestines,
stomach, and brain (Figure 3-2). In normal mice the order of percentage accumulation
was: blood>liver>kidney>lung>spleen>heart. Studies revealed 1.8%, 1.1% and 0.4% of
total DNAzyme injected was delivered to liver, kidney, and lung, respectively (Table
3-1). In MMTV-PyMT mice bearing small to large mammary tumors, the order of
percentages of [35S]-DNAzyme accumulation in different organs was
mammary tumor>liverblood>kidney>spleen>lung>heart. In these mice, 4.1% of the
total injected DNAzyme was accumulated in the mammary tumors in 2 h (Table 3-3) and
the amount of DNAzyme accumulated in mammary tumors was proportional to the total
weight of tumor burden (Figure 3-4). Interestingly, the accumulated DNAzyme in the
mammary tumor is initially cleared at a slower rate compared to the other organs. The
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percentages of total DNAzyme accumulated in various organs in MMTV-PyMT mice
were similar to normal mice (Table 3-1 and 3-3). In normal and MMTV-PyMT mice the
majority of the DNAzyme was cleared from these organs within the first 24 h. Thirty-one
percent of the delivered dosage of [35S]-DNAzyme was cleared from the system of
normal mice via feces and urine over a period of 72 h (Figure 3-1b). The safety of
DNAzyme was tested by a single injection or AM9D or control DNAzyme in various
concentrations (10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) and 100 l PBS into
normal FVB mice. Systemic distribution and safety/toxicity studies revealed that the
naked AM9D is non-toxic when systemically administered, and has favorable
pharmacological properties with respect to intravenous administration and tissue
distribution. Most importantly, mammary tumors can take up the naked DNAzyme. The
amount of DNAzyme accumulates in the mammary gland is higher and its rate of
clearance is slower than any other organs tested. Taken together, these data show the
potential of DNAzymes to be distributed to organs susceptible to tumors (brain, pancreas,
stomach, etc.), taken up by tumors, and display extended half-life in tumors.
AM9D and control DNAzyme both showed evidence of a possible sequence
related affect on metastasis when used as therapy for early stage experimental metastases.
This may be due to AM9D and control DNAzyme containing CpG regions. CpG
monotherapy has been shown to induce T-cell-mediated rejection of established tumors
[91]. Assessment of long term lung tumor burden and survival suggests that AM9D
treated mice have an advantage of progression-free survival over mice treated with
control DNAzyme or PBS between days 32-42, however, all cohorts were eventually
overcome by an equal volume of lung tumor burden (Figure 4-4) and there was no
advantage of overall survival in either groups. This lack of effect maybe due to time of
AM9D delivery, frequency of delivery, mouse strain, pro-tumorigenic effects of MMP-9
downregulation, or a combination of these effects. These are all concerns that must be
investigated to confirm the anti-metastatic effect of AM9D.
Finally, in this body of work we showed that MMP-9, through its cleavage of type
I collagen, might play a more important role in tumorigenesis than once believed. We
have demonstrated that 68 kDa truncated fully processed MMP-9 in addition to type IV
collagen, is capable of cleaving type I collagen. Kinetic analysis of truncated MMP-9
demonstrated that amino acid sequence 444-456 in the hinge region of MMP-9 is
responsible for substrate specificity of the enzyme. The absence of this region in
CT(1-443) and 444-502 garnered these enzymes with type I collagenolytic activity.
Further analysis of amino acid sequence 444-456 identified the two amino acids Glu447
and Arg451 as being directly involved in substrate recognition by the enzyme. Substitution
of Glu415 with Gly and/or replacement of Glu447 and Arg451 with Ala in CT(1-456) made
the enzyme capable of using type I collagen as a substrate. The catalytic efficiency of the
double mutant (E415G/E447A/CT(1-456)) toward type I collagen was 2-fold higher than
either E415G or E447A mutant, indicating that interaction of Glu415 with Glu447 dictates
substrate specificity of the enzyme. Lack of this interaction makes the active site flexible,
allowing the enzyme to cleave both type IV and I collagen, the two most important
components of the ECM. This observation is important because it further illuminates the
role of MMP-9 in tumorigenesis and metastases.
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CHAPTER 7.

AM9D: FROM PRECLINIC TO CLINIC

AM9D FOR BREAST CANCER PATIENTS
There are several lines of evidence that suggest MMP-9 levels in serum and tissue
could be a sensitive biomarker for tumor aggressiveness and metastasis in breast cancer
patients [111-115]. Moses, et al. first described that the analysis of urinary MMP-9 may
be a useful determinant for disease status in a variety of human cancers, including breast
cancer [113]. In this study, urine specimens were obtained from patients prior to surgical
or other therapeutic intervention and all breast cancer urine specimens were obtained
from patients with metastatic disease. One hundred percent of these specimens were
positive for MMP-9 compared to only 24% of normal control breast tissue [113].
Pellikainen, et al. evaluated the expression of MMP-9 in estrogen receptor positive
(ER+/HER2) breast cancer patients and discovered positive stromal MMP-9 expression
predicted decreased progression-free survival and decreased overall survival [116].
Furthermore, Wu, et al. measured serum and tissue levels of MMP-9 in breast cancer
patients, benign breast disease patients, and healthy controls and correlated the levels
with patients’ clinicopathologic characteristics [112]. Sixty-three and 77% of the breast
cancer patients displayed high MMP-9 serum levels and tissue staining, respectively, that
positively correlated with lymph node metastasis [112].
As described earlier (Chapter 1), breast cancer is divided into 3 subtypes: luminal
A (ER or PR+/HER2-), luminal B (ER or PR+/HER2+), and triple negative
(ER-/PR-/HER2-). Interestingly, MMP-9 serum levels were equally increased in HER2+
and HER2- patients, as well as, ER+ and ER- breast cancer patients [112]. Triple negative
breast cancer accounts for approximately 15% of breast cancer cases and is marked with
high relapse rates, metastasis, and early death [117]. In a comparison of breast cancer
patients with triple-negative or HER2 overexpression, the triple-negative patients
experienced more lymph node metastasis compared to those with overexpressed HER2
[118]. MMP-9 expression was positively correlated with lymph node metastasis in breast
cancer patients [112]. Additionally, the 5 year disease-free survival in patients with
triple-negative was much shorter than HER2-expressing patients [118]. The lack of
standard therapy and poor prognosis are causes of the high mortality [117]. Targeting
MMP-9 that has been shown to be expressed in hormone positive and negative breast
cancer patients, could play an important role in tumor treatment and reduce metastasis to
lymph nodes and other metastatic sites of breast cancer patients. We have shown the
distribution of MMP-9 DNAzyme (AM9D) to all major organs, including lung, brain and
liver (Chapter 3, Figure 3-2). To this end, AM9D will be a useful therapeutic treatment
for hormone positive and negative breast cancer patients at the early stages of tumor
growth and metastasis.
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AM9D AS AN ADJUVANT TO SURGERY
MMPs play a role in the normal physiology and pathology of wound healing.
When tissue suffers injury cell proliferation increases, inflammatory cells infiltrate the
wounded area and release MMPs, including MMP-9, while the tissue regenerates [119].
A first line treatment for breast tumor is surgical excision. Zhao, et al., demonstrated that
surgical excision of an implanted MDA-MB-245 mammary tumor in mice led to
increased serum expression of MMP-9 on days 1, 3, 19, 26, 33, and 40 after surgical site
wounding compared to non-surgical tumor bearing control cohorts [115]. This increased
MMP-9 expression was positively correlated with the increased tumor volume in the
surgery group between weeks 4-6 compared to the control group. Furthermore, elevated
host serum MMP-9 levels, as a result of surgery wound, was positively correlated to
metastatic lung tumor burden at the study endpoint [115]. To my knowledge, no studies
have been performed on breast cancer patients to determine the levels of MMP-9 serum
expression post surgical incision. However, if MMP-9 serum expressions in patients
mimic those of preclinical studies, AM9D would play an important therapeutic role as an
adjuvant to breast tumor surgery to abate tumor metastasis and surgery-stimulated growth
at the site of excision.
FUTURE AM9D PRECLINICAL STUDIES
MMPs are considered promising targets for breast cancer therapy because of their
major involvement in malignant pathologies and metastasis to distant organs [120]. The
preclinical studies outlined in this body of work further display the therapeutic potential
of downregulating MMP-9 expression by an MMP-9 specific catalytic DNA molecule.
While we show the efficacy of AM9D on reducing tumor growth (Chapter 2), its
efficiency on inhibition of metastasis needs to be further explored. We displayed that a
majority of DNAzyme is cleared from major organs, including lung, in the first 24 h
(Chapter 3, Figures 3-1 and 3-3). The chronic cytotoxicity experiments for DNAzyme
were performed with weekly injections of DNAzyme for 9 weeks (Chapter 4, Figure
4-5). To further explore AM9D efficacy on the treatment of metastasis, a therapeutically
efficient regimen must be determined. To accomplish this goal DNAzyme injections
could be increased from weekly to daily injections over a period of 3 weeks for survival
analysis upon early stage metastasis and until mice are overcome by tumor burden.
Performing daily injections of 75 mg/kg AM9D for a period of 3 weeks would expose
animals to a total of 1,575 mg/kg DNAzyme, which would require re-evaluation of mice
for cytotoxicity. This would be a 7-fold increase from the original 225 mg/kg injected in
previous experiments and should escalate DNAzyme accumulation in major organs.
If multiple injections prove to be too cumbersome, DNAzyme can be packaged
into nanoparticles as an alternate delivery approach. Designing nanoparticles has the
added effect of targeting two metastatic sites, such as lung and liver, simultaneously
[121]. Targeted delivery is a promising method for the development of efficient and safe
therapeutic molecules for oncology [122]. Rapid vasculature development in tumor
results in larger than normal pore size within vessel walls, which allows nanoparticles to
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more easily extravasate into tumor tissue than normal tissue [123]. Tumor tissues also
contain a deficiently developed lymphatic system that limits drainage of nanoparticles.
Therefore, nanoparticles can improve the accumulation of DNAzyme within the tumor
through their enhanced permeability and retention capabilities [123]. Similar to our
observations of DNAzyme clearance (Chapter 3), Bellocq, et al. showed the majority of
systemically administered DNAzyme cleared from organs after 24 h in mice. However,
they found that injecting DNAzyme packaged with transferrin-modified polyplexes
nanoparticle resulted in slower clearance of DNAzyme compared to DNAzyme packaged
with non-modified polyplexes [121]. Transferrin receptor (Tf-R) is often upregulated in
rapidly growing cells; furthermore, lung and liver both have high Tf-R expression [121].
Packaging our AM9D with transferrin-modified polyplexes would require additional
functional and pharmacokinetic studies; however, this could decrease non-specific
distribution throughout the body, decrease the observed rapid excretion, and increase
accumulation thereby eliminating the need for daily injections of AM9D.
In lieu of the emerging organ toxicities and side effects of broad spectrum
inhibitors, including tyrosine kinase inhibitors [124], we cannot ignore the possibility of
AM9D side effects surfacing. While we showed no evidence of organ toxicity in mice
injected with DNAzyme (Chapter 3), we negated to observe normal mammary tissue for
the presence of toxicity in these studies. MMP-9 has been shown to be present in normal
breast tissue [125]. To my knowledge, there are no studies outlining a clear role of
MMP-9 in normal breast tissue. Therefore, the down regulation of MMP-9 in normal
breast tissue by AM9D may lead to potential side effects. Any possible toxicities may be
found through the investigation of MMP-9 in normal breast tissue in the absence and
presence of AM9D.
AM9D opens the door to the development of effective anti-MMP therapies.
AM9D could be used as a therapy for hormone positive and negative breast cancer
patients as an adjuvant to surgery and in combination with other chemotherapeutic
modalities. Overall, AM9D shows promise as a therapeutic modality for breast cancer
treatment and warrants further investigation.

66

LIST OF REFERENCES
1.

Society AC (2009). Breast Cancer Facts and Figures 2009-2010, American
Cancer Society, Inc. : Atlanta, GA.

2.

Hu X, et al. (2009). Genetic alterations and oncogenic pathways associated with
breast cancer subtypes. Mol Cancer Res 7: 511-522.

3.

Boyce BF, Yoneda T, Guise TA (1999). Factors regulating the growth of
metastatic cancer in bone. Endocr Relat Cancer 6: 333-347.

4.

Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic
opportunities. Nat Rev Cancer 2: 584-593.

5.

Duffy MJ, McGowan PM, Gallagher WM (2008). Cancer invasion and
metastasis: changing views. J Pathol 214: 283-293.

6.

Minn AJ, et al. (2005). Distinct organ-specific metastatic potential of individual
breast cancer cells and primary tumors. J Clin Invest 115: 44-55.

7.

Kang Y, et al. (2003). A multigenic program mediating breast cancer metastasis
to bone. Cancer Cell 3: 537-549.

8.

Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ (1997).
Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations
that leads to stable epithelial-to-mesenchymal conversion and a premalignant
phenotype in mammary epithelial cells. J Cell Biol 139: 1861-1872.

9.

Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in
cancer progression. Nat Rev Cancer 2: 161-174.

10.

Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of
proteases. Nat Rev Cancer 3: 489-501.

11.

Birkedal-Hansen H, et al. (1993). Matrix metalloproteinases: a review. Crit Rev
Oral Biol Med 4: 197-250.

12.

Nenan S, Boichot E, Lagente V, Bertrand CP (2005). Macrophage elastase
(MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz 100 Suppl 1:
167-172.

13.

Billinghurst RC, et al. (1997). Enhanced cleavage of type II collagen by
collagenases in osteoarthritic articular cartilage. J Clin Invest 99: 1534-1545.

14.

Nap AW, Dunselman GA, de Goeij AF, Evers JL, Groothuis PG (2004).
Inhibiting MMP activity prevents the development of endometriosis in the
chicken chorioallantoic membrane model. Hum Reprod 19: 2180-2187.
67

15.

Aimes RT, Quigley JP (1995). Matrix metalloproteinase-2 is an interstitial
collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and
soluble native type I collagen generating the specific 3/4- and 1/4-length
fragments. J Biol Chem 270: 5872-5876.

16.

Okada Y, et al. (1992). Matrix metalloproteinase 9 (92-kDa gelatinase/type IV
collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation
of the precursor and enzymic properties. J Biol Chem 267: 21712-21719.

17.

Martin MD, Matrisian LM (2007). The other side of MMPs: protective roles in
tumor progression. Cancer Metastasis Rev 26: 717-724.

18.

Overall CM (2002). Molecular determinants of metalloproteinase substrate
specificity: matrix metalloproteinase substrate binding domains, modules, and
exosites. Mol Biotechnol 22: 51-86.

19.

Coussens LM, Fingleton B, Matrisian LM (2002). Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.

20.

Wolf K, Sandner P, Kurtz A, Moll W (1996). Messenger ribonucleic acid levels
of collagenase (MMP-13) and matrilysin (MMP-7) in virgin, pregnant, and
postpartum uterus and cervix of rat. Endocrinology 137: 5429-5434.

21.

Woessner JF, Jr., Gunja-Smith Z (1991). Role of metalloproteinases in human
osteoarthritis. J Rheumatol Suppl 27: 99-101.

22.

Nagase H, Visse R, Murphy G (2006). Structure and function of matrix
metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573.

23.

Gavrilovic J, Moens G, Thiery JP, Jouanneau J (1990). Expression of transfected
transforming growth factor alpha induces a motile fibroblast-like phenotype with
extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell
Regul 1: 1003-1014.

24.

Martorana AM, Zheng G, Crowe TC, O'Grady RL, Lyons JG (1998). Epithelial
cells up-regulate matrix metalloproteinases in cells within the same mammary
carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res
58: 4970-4979.

25.

Hojilla CV, Mohammed FF, Khokha R (2003). Matrix metalloproteinases and
their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89:
1817-1821.

26.

Shima I, et al. (1993). Production of matrix metalloproteinase 9 (92-kDa
gelatinase) by human oesophageal squamous cell carcinoma in response to
epidermal growth factor. Br J Cancer 67: 721-727.

68

27.

Overall CM, Kleifeld O (2006). Tumour microenvironment - opinion: validating
matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat
Rev Cancer 6: 227-239.

28.

Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y (1993). Matrix
metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937
monoblastoid cells: correlation with cellular invasion. J Cell Sci 104 ( Pt 4): 991999.

29.

Cha HJ, et al. (1996). Anti-invasive activity of ursolic acid correlates with the
reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human
fibrosarcoma cells. Cancer Res 56: 2281-2284.

30.

Bergers G, et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol 2: 737-744.

31.

Xu J, et al. (2001). Proteolytic exposure of a cryptic site within collagen type IV
is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 10691079.

32.

Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS (2008).
Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is
mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol
Chem 283: 1545-1552.

33.

Matrisian LM, et al. (1986). The mRNA coding for the secreted protease transin
is expressed more abundantly in malignant than in benign tumors. Proc Natl Acad
Sci U S A 83: 9413-9417.

34.

Liotta LA, Rao CN, Wewer UM (1986). Biochemical interactions of tumor cells
with the basement membrane. Annu Rev Biochem 55: 1037-1057.

35.

Chintala SK, Tonn JC, Rao JS (1999). Matrix metalloproteinases and their
biological function in human gliomas. Int J Dev Neurosci 17: 495-502.

36.

Morini M, et al. (2000). The alpha 3 beta 1 integrin is associated with mammary
carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J
Cancer 87: 336-342.

37.

Bernhard EJ, Gruber SB, Muschel RJ (1994). Direct evidence linking expression
of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic
phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 91: 42934297.

38.

Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P (2010).
Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human
breast cancer cell line. Eur J Pharmacol 627: 8-15.
69

39.

Overall CM, Lopez-Otin C (2002). Strategies for MMP inhibition in cancer:
innovations for the post-trial era. Nat Rev Cancer 2: 657-672.

40.

O'Farrell TJ, Pourmotabbed T (1998). The fibronectin-like domain is required for
the type V and XI collagenolytic activity of gelatinase B. Arch Biochem Biophys
354: 24-30.

41.

Smyth E (2003). The Trouble with Inhibitors. In Horizon Symposia Signalling
Scissors: New Perspectives on Proteases, pp. 1-4.

42.

Haq M, Shafii A, Zervos EE, Rosemurgy AS (2000). Addition of matrix
metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor
implantation and prolongs survival in a murine model of human pancreatic
cancer. Cancer Res 60: 3207-3211.

43.

Zervos EE, Shafii AE, Rosemurgy AS (1999). Matrix metalloproteinase (MMP)
inhibition selectively decreases type II MMP activity in a murine model of
pancreatic cancer. J Surg Res 81: 65-68.

44.

Bloomston M, Zervos EE, Rosemurgy AS, 2nd (2002). Matrix metalloproteinases
and their role in pancreatic cancer: a review of preclinical studies and clinical
trials. Ann Surg Oncol 9: 668-674.

45.

Bramhall SR, et al. (2002). Marimastat as maintenance therapy for patients with
advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870.

46.

Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997). Matrix
metalloproteinase inhibitors. Invest New Drugs 15: 61-75.

47.

Rasmussen HS, McCann PP (1997). Matrix metalloproteinase inhibition as a
novel anticancer strategy: a review with special focus on batimastat and
marimastat. Pharmacol Ther 75: 69-75.

48.

Khachigian LM (2000). Catalytic DNAs as potential therapeutic agents and
sequence-specific molecular tools to dissect biological function. J Clin Invest 106:
1189-1195.

49.

Santoro SW, Joyce GF (1998). Mechanism and utility of an RNA-cleaving DNA
enzyme. Biochemistry 37: 13330-13342.

50.

Dass CR, Choong PF, Khachigian LM (2008). DNAzyme technology and cancer
therapy: cleave and let die. Mol Cancer Ther 7: 243-251.

51.

Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A (2002). c-Jun
regulates vascular smooth muscle cell growth and neointima formation after
arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem
277: 22985-22991.
70

52.

Qu Y, et al. (2008). Effects of DNAzymes targeting Aurora kinase A on the
growth of human prostate cancer. Cancer Gene Ther 15: 517-525.

53.

Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ (2002).
Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial
growth factor receptor 2. Cancer Res 62: 5463-5469.

54.

Noel A, Jost M, Maquoi E (2008). Matrix metalloproteinases at cancer tumor-host
interface. Semin Cell Dev Biol 19: 52-60.

55.

Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG,
Roberts AB (2005). Breast cancer cells induce stromal fibroblasts to express
MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118: 2143-2153.

56.

Fenhalls G, Geyp M, Dent DM, Parker MI (1999). Breast tumour cell-induced
down-regulation of type I collagen mRNA in fibroblasts. Br J Cancer 81: 11421149.

57.

Coussens LM, Werb Z (1996). Matrix metalloproteinases and the development of
cancer. Chem Biol 3: 895-904.

58.

Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET
(2004). Global expression profiling identifies signatures of tumor virulence in
MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64:
5973-5981.

59.

Lin EY, et al. (2003). Progression to malignancy in the polyoma middle T
oncoprotein mouse breast cancer model provides a reliable model for human
diseases. Am J Pathol 163: 2113-2126.

60.

Fantozzi A, Christofori G (2006). Mouse models of breast cancer metastasis.
Breast Cancer Res 8: 212.

61.

Ward J. The Virtual Mouse Necropsy. Comparative Medicine Branch, NIAID,
NIH. Accessed March 25, 2010. http://icg.cpmc.columbia.edu/cattoretti/Protocol/
FilesInPdf/NCIVetp.pdf.

62.

Lifsted T, et al. (1998). Identification of inbred mouse strains harboring genetic
modifiers of mammary tumor age of onset and metastatic progression. Int J
Cancer 77: 640-644.

63.

Herschkowitz JI, et al. (2007). Identification of conserved gene expression
features between murine mammary carcinoma models and human breast tumors.
Genome Biol 8: R76.

64.

Pedersen TX, et al. (2005). Extracellular protease mRNAs are predominantly
expressed in the stromal areas of microdissected mouse breast carcinomas.
Carcinogenesis 26: 1233-1240.
71

65.

Szabova L, Yamada SS, Birkedal-Hansen H, Holmbeck K (2005). Expression
pattern of four membrane-type matrix metalloproteinases in the normal and
diseased mouse mammary gland. J Cell Physiol 205: 123-132.

66.

Almholt K, Green KA, Juncker-Jensen A, Nielsen BS, Lund LR, Romer J (2007).
Extracellular proteolysis in transgenic mouse models of breast cancer. J
Mammary Gland Biol Neoplasia 12: 83-97.

67.

Almholt K, et al. (2008). Metastasis is strongly reduced by the matrix
metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast
cancer model. Mol Cancer Ther 7: 2758-2767.

68.

Martin MD, et al. (2008). Effect of ablation or inhibition of stromal matrix
metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on
genetic background. Cancer Res 68: 6251-6259.

69.

Mitchell A, Dass CR, Sun LQ, Khachigian LM (2004). Inhibition of human breast
carcinoma proliferation, migration, chemoinvasion and solid tumour growth by
DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids
Res 32: 3065-3069.

70.

Berger AC, et al. (2005). Colon cancer survival is associated with decreasing ratio
of metastatic to examined lymph nodes. J Clin Oncol 23: 8706-8712.

71.

Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR (2008). BRMS1
suppresses breast cancer experimental metastasis to multiple organs by inhibiting
several steps of the metastatic process. Am J Pathol 172: 809-817.

72.

Vasselli JR, et al. (2003). Predicting survival in patients with metastatic kidney
cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S
A 100: 6958-6963.

73.

Jones JL, Glynn P, Walker RA (1999). Expression of MMP-2 and MMP-9, their
inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol
189: 161-168.

74.

Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N (2000).
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast
Cancer Res 2: 252-257.

75.

Pourmotabbed T, Solomon TL, Hasty KA, Mainardi CL (1994). Characteristics of
92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells:
structure, expression of cDNA in E. coli and enzymic properties. Biochim Biophys
Acta 1204: 97-107.

76.

Agrawal S, Temsamani J, Tang JY (1991). Pharmacokinetics, biodistribution, and
stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci
U S A 88: 7595-7599.
72

77.

Lau DH, Xue L, Young LJ, Burke PA, Cheung AT (1999). Paclitaxel (Taxol): an
inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.
Cancer Biother Radiopharm 14: 31-36.

78.

Dass CR, Choong PF (2010). Sequence-related off-target effect of Dz13 against
human tumor cells and safety in adult and fetal mice following systemic
administration. Oligonucleotides 20: 51-60.

79.

Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY (2006). The effects of curcumin on
the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic
Dis 9: 147-152.

80.

Lee KW, Kim JH, Lee HJ, Surh YJ (2005). Curcumin inhibits phorbol esterinduced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by
blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in
MCF10A human breast epithelial cells. Antioxid Redox Signal 7: 1612-1620.

81.

Aggarwal BB, et al. (2005). Curcumin suppresses the paclitaxel-induced nuclear
factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of
human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498.

82.

Eiseler T, Doppler H, Yan IK, Goodison S, Storz P (2009). Protein kinase D1
regulates matrix metalloproteinase expression and inhibits breast cancer cell
invasion. Breast Cancer Res 11: R13.

83.

Chen X, et al. (2005). Increased plasma MMP9 in integrin alpha1-null mice
enhances lung metastasis of colon carcinoma cells. Int J Cancer 116: 52-61.

84.

Itoh T, et al. (1999). Experimental metastasis is suppressed in MMP-9-deficient
mice. Clin Exp Metastasis 17: 177-181.

85.

Gerg M, et al. (2008). Distinct functionality of tumor cell-derived gelatinases
during formation of liver metastases. Mol Cancer Res 6: 341-351.

86.

Rao VH, et al. (1995). Expression of 72 kDa and 92 kDa type IV collagenases
from human giant-cell tumor of bone. Clin Exp Metastasis 13: 420-426.

87.

Lewis CE, Pollard JW (2006). Distinct role of macrophages in different tumor
microenvironments. Cancer Res 66: 605-612.

88.

Rijnkels M, Rosen JM (2001). Adenovirus-Cre-mediated recombination in
mammary epithelial early progenitor cells. J Cell Sci 114: 3147-3153.

89.

Krieg AM (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat
Rev Drug Discov 5: 471-484.

90.

Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ (2002). Toll-like receptor 9
mediates CpG-DNA signaling. J Leukoc Biol 71: 538-544.
73

91.

Krieg AM (2004). Antitumor applications of stimulating toll-like receptor 9 with
CpG oligodeoxynucleotides. Curr Oncol Rep 6: 88-95.

92.

Shibue T, Weinberg RA (2009). Integrin beta1-focal adhesion kinase signaling
directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc
Natl Acad Sci U S A 106: 10290-10295.

93.

Wyatt CA, Geoghegan JC, Brinckerhoff CE (2005). Short hairpin RNA-mediated
inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix
destruction and tumor growth. Cancer Res 65: 11101-11108.

94.

Hughes S, et al. (2007). Matrix metalloproteinase single-nucleotide
polymorphisms and haplotypes predict breast cancer progression. Clin Cancer
Res 13: 6673-6680.

95.

Provatopoulou X, et al. (2009). Circulating levels of matrix metalloproteinase-9
(MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex
MMP-9/NGAL in breast cancer disease. BMC Cancer 9: 390.

96.

Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A (2005). PAR1 is
a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of
breast cancer cells. Cell 120: 303-313.

97.

Bu CH, Pourmotabbed T (1995). Mechanism of activation of human neutrophil
gelatinase B. Discriminating between the role of Ca2+ in activation and catalysis.
J Biol Chem 270: 18563-18569.

98.

Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G (1995).
Binding of gelatinases A and B to type-I collagen and other matrix components.
Biochem J 309 ( Pt 1): 299-306.

99.

O'Farrell TJ, Pourmotabbed T (2000). Identification of structural elements
important for matrix metalloproteinase type V collagenolytic activity as revealed
by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase
B. J Biol Chem 275: 27964-27972.

100.

Abecassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A (2003). RhoA
induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes
HMEC-1 cell invasion. Exp Cell Res 291: 363-376.

101.

Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J (2010). Role of matrix
metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol
Chem 285: 35944-35956.

102.

Behzadian MA, Wang XL, Windsor LJ, Ghaly N, Caldwell RB (2001). TGF-beta
increases retinal endothelial cell permeability by increasing MMP-9: possible role
of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 42: 853859.
74

103.

Roeb E, et al. (2002). The matrix metalloproteinase 9 (mmp-9) hemopexin
domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem
277: 50326-50332.

104.

Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H (1992). Purification
and characterization of matrix metalloproteinase 9 from U937 monocytic
leukaemia and HT1080 fibrosarcoma cells. Biochem J 285 ( Pt 2): 603-611.

105.

O'Farrell TJ, Guo R, Hasegawa H, Pourmotabbed T (2006). Matrix
metalloproteinase-1 takes advantage of the induced fit mechanism to cleave the
triple-helical type I collagen molecule. Biochemistry 45: 15411-15418.

106.

Pourmotabbed T, Aelion JA, Tyrrell D, Hasty KA, Bu CH, Mainardi CL (1995).
Role of the conserved histidine and aspartic acid residues in activity and
stabilization of human gelatinase B: an example of matrix metalloproteinases. J
Protein Chem 14: 527-535.

107.

Tsukada H, Pourmotabbed T (2002). Unexpected crucial role of residue 272 in
substrate specificity of fibroblast collagenase. J Biol Chem 277: 27378-27384.

108.

Harris ED, Jr., Krane SM (1972). An endopeptidase from rheumatoid synovial
tissue culture. Biochim Biophys Acta 258: 566-576.

109.

Bu CH, Pourmotabbed T (1996). Mechanism of Ca2+-dependent activity of
human neutrophil gelatinase B. J Biol Chem 271: 14308-14315.

110.

Rowsell S, et al. (2002). Crystal structure of human MMP9 in complex with a
reverse hydroxamate inhibitor. J Mol Biol 319: 173-181.

111.

Zucker S, Lysik RM, Zarrabi MH, Moll U (1993). M(r) 92,000 type IV
collagenase is increased in plasma of patients with colon cancer and breast cancer.
Cancer Res 53: 140-146.

112.

Wu ZS, et al. (2008). Prognostic significance of MMP-9 and TIMP-1 serum and
tissue expression in breast cancer. Int J Cancer 122: 2050-2056.

113.

Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman
MR (1998). Increased incidence of matrix metalloproteinases in urine of cancer
patients. Cancer Res 58: 1395-1399.

114.

Hemati S, Sadeghi, M., Motovali-Bashi, M., Sahebi, A., Vaise Malekshahi, Z.
(2010). Higher plasma MMP-9 level in breast cancer patients with MMP-9
promoter T allele. J Biol Res - Thessalon 13: 113-118.

115.

Zhao T, Xia WH, Zheng MQ, Lu CQ, Han X, Sun YJ (2008). Surgical excision
promotes tumor growth and metastasis by promoting expression of MMP-9 and
VEGF in a breast cancer model. Exp Oncol 30: 60-64.
75

116.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma
VM (2004). Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in
breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Clin Cancer Res 10: 7621-7628.

117.

Oakman C, Viale G, Di Leo A (2010). Management of triple negative breast
cancer. Breast 19: 312-321.

118.

Wang YJ, Wang N, Wang B, Qin WX, Xue CY (2009). [Comparison of
clinicopathologic characteristics and prognosis of triple-negative with Her-2overexpressing breast cancer]. Zhonghua Zhong Liu Za Zhi 31: 346-350.

119.

Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420: 860-867.

120.

Mannello F (2006). Natural bio-drugs as matrix metalloproteinase inhibitors: new
perspectives on the horizon? Recent Pat Anticancer Drug Discov 1: 91-103.

121.

Bellocq NC, Pun SH, Jensen GS, Davis ME (2003). Transferrin-containing,
cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug
Chem 14: 1122-1132.

122.

Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007). Impact of
tumor-specific targeting on the biodistribution and efficacy of siRNA
nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U
S A 104: 15549-15554.

123.

MacEwan SR, Callahan DJ, Chilkoti A (2010). Stimulus-responsive
macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond)
5: 793-806.

124.

Lodish MB, Stratakis CA (2010). Endocrine side effects of broad-acting kinase
inhibitors. Endocr Relat Cancer 17: R233-244.

125.

Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009). Expression of
matrix metalloproteinases (MMPs) in primary human breast cancer and breast
cancer cell lines: New findings and review of the literature. BMC Cancer 9: 188.

126.

Santoro SW, Joyce GF (1997). A general purpose RNA-cleaving DNA enzyme.
Proc Natl Acad Sci U S A 94: 4262-4266.

76

APPENDIX. DEVELOPMENT OF AM9D MATERIALS AND METHODS
DNAZYME
Several DNAzyme molecules were synthesized by Integrated DNA Technology
(Coralville, IA). All the DNAzymes consisted of nine oligonucleotides on each arms
complementary to different regions of MMP-9 mRNA flanking the nucleotide 10-23
catalytic core [49, 126]. Sequences of DNAzymes targeting mRNA of MMP-9 were,
AM9D-1: 5’-AGCCCAGCAggctagctacaacgaCAGGAGCAC-3’;
AM9D-2: 5’-AAGGGTGGAggctagctacaacgaTGGCGCTGT-3’;
AM9D-3 5’-ATAGCGGTAggctagctacaacgaAGGTATTCC-3’;
AM9D-4: 5’-CCCCAGAGAggctagctacaacgaTTCGACTCT-3’;
AM9D-5: 5’-GTGGTGCCAggctagctacaacgaTTGAGGTCG-3’. Scrambled DNAzyme
(CTAGTCAGCggctagctacaacgaTAAGCTGCT), where the arms flanking the 10-23
catalytic core were composed of random sequence and sense control DNAzymes
containing sense oligonucleotide sequences corresponding to each DNAzyme in both
arms were used as negative controls. Nucleotides in lower case represent the 10-23
catalytic domain and the corresponding MMP-9 sequences are in capital. Where
indicated, DNAzymes were fluorescently labeled at 5’ end with Oregon Green 488
maleimide as suggested by the manufacture (Molecular Probes, Eugene, OR). The
labeled oligonucleotides were purified with the MERmaid Kit (BIO 101, La Jolla, CA).
IN VITRO TRANSCRIPTION AND CLEAVAGE ANALYSIS OF MMP-9 RNA BY
DNAZYMES
The 764-nucleotide MMP-9 RNA transcript was prepared by in vitro
transcription (T3 polymerase) of pBSNG4.1 [75] digested with Bsm1 restriction
enzyme. DNAzymes (12.5 μM) were incubated with the RNA substrate (0.48 μM) in
50 mM Tris-HCl, pH 7.5, containing 10 mM MgCl2 at 37 ˚C for 2 h. The reactions were
stopped with 90% formamide in TBE and the reaction products were separated on a 4%
polyacrylamide-urea gel. The RNA products were stained with Ethidium Bromide and
their intensities were determined using an Alpha Imager 2000 documentation and
analysis system (Alpha Innotech Corp., San Leandro, CA).
CELL TRANSFECTION
The COS-7 and MDA-MB-231 cell lines were obtained from American Type
Culture Collection (ATTC, Manassas, VA). COS-7 cells were grown in Dulbecco’s
modified Eagles medium (DMEM), pH 7.4, containing 10% fetal bovine serum (FBS),
100 i.u./ml penicillin, and 100 μg/ml streptomycin at 37 ˚C in a humidified atmosphere
of 10% CO2. The COS-7 NG was generated by stably transfecting COS-7 cells with
pcDNA3-MMP-9. Sub-confluent COS-7 NG cells (60-70%) were incubated in serum
free medium and transiently transfected with Oregon Green 488 maleimide labeled
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DNAzyme (AM9D-5; 24 μg) using DOTAP transfection reagent according to the
manufacturer’s instruction (Roche, Mannheim, Germany). After 24 h incubation at
37 ˚C in serum free medium, cells were collected, sorted, and the transfected cells were
isolated for further analysis. MDA-MB-231 human breast cancer cells (ATCC;
Manassas, VA) were plated onto 10 cm dishes in DMEM media supplemented with 10%
fetal bovine serum (FBS) and allowed to grow to 80-90% confluence at 37 ˚C with 5%
CO2. The cells were then serum-starved for 4 hours prior to transient transfection with
Oregon Green 488-maleimide -labeled AM9D-5 or control DNAzyme (24 μg) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After a 18 h incubation at 37 ˚C in
serum free medium, transfected cells were sorted for the presence of Oregon Green on a
BD Biosciences Aria cytometer and positive cells were collected for further analysis.
ANALYSIS OF MMP-9 MRNA AND PROTEIN PRODUCTION IN AM9D
TRANSFECTED CELLS
The amount of MMP-9 mRNA and its enzyme activity in the DNAzyme
transfected COS-7 NG cells were measured by reverse transcription-polymerase chain
reaction (RT-PCR) and gelatin gel zymography [75], respectively. Total RNA from the
transfected COS-7 NG cells was isolated by Trizol reagent (Invitrogen, Carlsbad, CA)
and reverse transcribed with random hexamer primers (Promega, Madison, WI) using
MMLV-RT enzyme (Invitrogen, Carlsbad, CA). The amount of MMP-9 mRNA present
in the RNA samples was quantified by PCR using specific MMP-9 primers (forward;
5’-GCAGGAATGCGGCTCTGG-3’ and reverse primer;
5’-CCCGTCGAAGGGATACC-3’). -actin mRNA was also amplified as an internal
control, with forward; 5’-CAAGAGATGGCCACGGCGGCT-3’ and reverse;
5’-TCCTTCTGCATCCTGTCAGCA-3’ Primers. The PCR products were subjected to
1% agarose gel and visualized by Ethidium Bromide staining. MMP-9 expression was
quantified by an alpha imager 2000 documentation and analysis system (Alpha Innotech
corporation San Leandro, CA).
CELL INVASION ASSAY
MDA-MB-231 cells were transfected with fluorescently labeled AM9D-5 or
control DNAzyme for 18 h in serum free DMEM medium as above. The fluorescent
positive cells was identified by flow cytometry, isolated and seeded in ECMatrix™
invasion chambers (Millipore, Billerica, MA). After 24 h incubation at 37 ˚C with 5%
CO2, the number of cells that migrated though the ECM layer and attached to the
polycarbonate membrane was quantified spectrophotometerically at 560 nm according
to the manufacturer’s protocol. All assays were conducted in triplicate and the values
were averaged.
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